<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1612223019
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Delstrigo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DORAVIRINE,LAMIVUDINE,TENOFOVIR DISOPROXIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,300,245
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2413.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Delstrigo is</strong></p><p>Delstrigo is used to treat HIV (&lsquo;human immunodeficiency virus&rsquo;) infection. It belongs to a group of medicines called &lsquo;antiretroviral medicines&rsquo;.</p><p>&nbsp;</p><p>Delstrigo contains the active substances:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Doravirine - a non-nucleoside reverse transcriptase inhibitor (NNRTI)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lamivudine - a nucleoside analogue reverse transcriptase inhibitor (NRTI)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tenofovir disoproxil - a nucleoside analogue reverse transcriptase inhibitor (NRTI)</p><p>&nbsp;</p><p><strong>What Delstrigo is used for</strong></p><p>Delstrigo is used to treat HIV infection in adults, and adolescents aged 12&nbsp;years and older weighing at least 35&nbsp;kg. HIV is the virus that causes AIDS (&lsquo;acquired immune deficiency syndrome&rsquo;). You should not take Delstrigo if your doctor has told you that the virus causing your infection is resistant to any of the medicines in Delstrigo.</p><p>&nbsp;</p><p><strong>How Delstrigo works</strong></p><p>Delstrigo works by preventing HIV from making more viruses in your body. This will help by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reducing the amount of HIV in your blood (this is called your &lsquo;viral load&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increasing the number of white blood cells called &lsquo;CD4<sup>+</sup> T&rsquo;. This can make your immune system stronger. This may reduce your risk of early death or catching infections because your immune system is weak.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Delstrigo</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to doravirine, lamivudine or tenofovir disoproxil or any of the other ingredients of this medicine listed in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp; carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for seizure)</p><p>-&nbsp;&nbsp; rifampicin, rifapentine (medicines for tuberculosis)</p><p>-&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>, a herbal remedy used for depression and anxiety) or products that contain it</p><p>-&nbsp;&nbsp; mitotane (a medicine to treat cancer)</p><p>-&nbsp;&nbsp; enzalutamide (a medicine to treat prostate cancer)</p><p>-&nbsp;&nbsp; lumacaftor (a medicine to treat cystic fibrosis)</p><p>&nbsp;</p><p>Do not take Delstrigo if the above applies to you. If you are not sure, talk to your doctor, pharmacist, or nurse before taking Delstrigo. See also the list in section &ldquo;Other Medicines and Delstrigo&rdquo;.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist, or nurse before taking Delstrigo.</p><p>&nbsp;</p><p><strong>Worsening of hepatitis B infection</strong></p><p>If you have both HIV and hepatitis B virus infections, your hepatitis B may get worse if you stop taking Delstrigo. You may require blood tests for several months after stopping treatment. Discuss your hepatitis B therapy with your doctor.</p><p>&nbsp;</p><p><strong>New or worsening kidney problems, including kidney failure</strong></p><p>This can happen in some people who take Delstrigo. Your doctor will do blood tests to check your kidney function before and during treatment with Delstrigo.</p><p>&nbsp;</p><p><strong>Bone problems</strong></p><p>This can happen in some people who take Delstrigo. Bone problems include bone pain, and bone softening or thinning (which may lead to fractures). Joint or muscle pain or muscle weakness may also occur. Your doctor may need to do additional tests to check your bones.</p><p>&nbsp;</p><p><strong>Immune reactivation syndrome</strong></p><p>This can happen when you start taking any HIV medicine, including Delstrigo. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your doctor right away if you start having any new symptoms after starting your HIV medicine.</p><p>&nbsp;</p><p>Autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>Do not give this medicine to children aged less than 12&nbsp;years or weighing less than 35&nbsp;kg.</strong> The use of Delstrigo in children aged less than 12&nbsp;years or weighing less than 35&nbsp;kg has not yet been studied.</p><p>&nbsp;</p><p><strong>Other medicines and Delstrigo</strong></p><p>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines. This is because other medicines may affect how Delstrigo works, and Delstrigo might affect the way some other medicines work.</p><p>&nbsp;</p><p>There are some medicines you must not take with Delstrigo. See list under &ldquo;Do not take Delstrigo&rdquo; section.</p><p>&nbsp;</p><p>Talk to your doctor before taking the following medicines with Delstrigo as your doctor may need to change the dose of your medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan (a medicine to treat lung disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dabrafenib (a medicine to treat skin cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lesinurad (a medicine to treat gout)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil (a medicine to treat excessive sleepiness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nafcillin (a medicine to treat some bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin (a medicine to treat some bacterial infections such as tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; telotristat ethyl (a medicine to treat diarrhea in people with carcinoid syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thioridazine (a medicine to treat psychiatric conditions such as schizophrenia)</p><p>&nbsp;</p><p>If your doctor decides you should take these medicines with Delstrigo, your doctor will prescribe a 100&nbsp;mg tablet of doravirine to be taken daily, approximately 12&nbsp;hours after your dose of Delstrigo.</p><p><strong>&nbsp;</strong></p><p>Your doctor may check your blood levels or monitor for side effects if you take the following medicines with Delstrigo:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ledipasvir/sofosbuvir (medicines used to treat hepatitis C infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus (a medicine used to control your body&rsquo;s immune response after a transplant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sofosbuvir/velpatasvir (medicines used to treat hepatitis C infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus (a medicine used to control your body&rsquo;s immune response after a transplant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><strong> </strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, talk to your doctor<strong> </strong>about the risks and benefits of taking Delstrigo. It is preferable to avoid the use of Delstrigo during pregnancy. This is because it has not been studied in pregnancy and it is not known if Delstrigo will harm your baby while you are pregnant.</p><p>&nbsp;</p><p>Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.</p><p><em>&nbsp;</em></p><p>If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Use with caution when driving, riding a bicycle, or operating machines if you feel tired, dizzy, or sleepy after taking this medicine</p><p>&nbsp;</p><p><strong>Delstrigo</strong><strong> tablets contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to lactose, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. Check with your doctor, pharmacist, or nurse if you are not sure. Delstrigo is a complete regimen taken as a single tablet for the treatment of HIV infection.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose is 1 tablet once a day. If you take certain medicines your doctor may need to change the amount of doravirine you take. See &ldquo;Other medicines and Delstrigo&rdquo; section for a list of medicines.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole (do not crush or chew).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine can be taken with food or between meals.</p><p>&nbsp;</p><p><strong>If you take more Delstrigo than you should</strong></p><p>Do not take more than the recommended dose. If you accidentally take more, contact your doctor.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Delstrigo</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that you do not miss or skip doses of Delstrigo.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget a dose, take it as soon as you remember. But if your next dose is due within 12&nbsp;hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take two doses of Delstrigo at the same time to make up for a missed dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not sure what to do, call your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you stop taking Delstrigo</strong></p><p>Do not run out of Delstrigo. Refill your prescription or talk to your doctor before your Delstrigo is all gone.</p><p>&nbsp;</p><p>If you stop taking Delstrigo, your doctor will need to check your health often and do blood tests regularly for several months to check your HIV infection. If you have HIV infection and hepatitis B infection, it is especially important not to stop your Delstrigo treatment without talking to your doctor first. Some patients have had blood tests or symptoms indicating that their hepatitis has worsened after stopping lamivudine or tenofovir disoproxil (two of the three active substances of Delstrigo). If Delstrigo is stopped your doctor may recommend that you resume hepatitis B treatment. You may need blood tests to check how your liver is working for 4&nbsp;months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Do not stop taking this medicine without first talking to your doctor.</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams, difficulty in sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, dizziness, sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, nasal symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), diarrhoea, stomach pain, vomiting, wind (flatulence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss, rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle symptoms (pain, stiffness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired, fever</p><p>&nbsp;</p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels in liver enzymes (ALT)</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nightmares, depression, anxiety, irritability, confusion, suicidal thoughts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble concentrating, memory problems, tingling of hands and feet, stiff muscles, poor quality of sleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, stomach discomfort, swollen or bloated stomach (abdominal distention), indigestion, soft stools, stomach spasms, frequent bowel movements, inflammation of the pancreas (pancreatitis) (causing stomach pain, vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain, breakdown of muscle tissue, muscular weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, general feeling of being unwell</p><p><strong>&nbsp;</strong></p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells in your blood (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of red blood cells in your blood (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of platelets in your blood (you may bleed more easily)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels phosphate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of potassium in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of creatinine in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels in liver enzymes (AST)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of lipase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of amylase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of haemoglobin</p><p>&nbsp;</p><p>The muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells.</p><p><strong>&nbsp;</strong></p><p><strong>Rare: </strong>may affect up to 1 in 1&nbsp;000 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression, hallucinations, difficulty adjusting to changes, mood changes, sleep walking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing, enlarged tonsils</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of incomplete defecation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged liver or fatty liver, yellow skin or eyes, pain in the belly (abdomen) caused by inflammation of the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin due to allergy, redness on the cheeks, nose, chin or forehead, bumps or pimples on the face, swelling of the face, lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, weakening of the bones (with bone pain and sometimes resulting in fractures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney damage, kidney stones, kidney failure, damage to kidney tubule cells, kidney injury, passing a lot of urine and feeling thirsty</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the chest, feeling cold, pain, thirst</p><p>&nbsp;</p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of magnesium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (excess lactic acid in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of creatine phosphokinase</p><p><strong>&nbsp;</strong></p><p><strong>Very rare: </strong>may affect up to 1 in 10&nbsp;000 people:</p><p><strong>&nbsp;</strong></p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure of the bone marrow to produce new red blood cells (pure red cell aplasia)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA&rdquo;. the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong>&bull;&nbsp;Store below 30˚C</p><p>&middot;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp; Do not use this medicine after the expiry date which is stated on the bottle after EXP.</p><p>&middot;&nbsp; The bottle contains desiccant protecting the tablets from moisture. There may be more than one in the bottle. Keep desiccant inside the bottle and do not throw away until you have finished taking all of the medicine.</p><p>&middot; Keep the bottle tightly closed in order to protect from moisture.</p><p>&middot; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Delstrigo contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are 100&nbsp;mg of doravirine, 300&nbsp;mg of lamivudine and 245&nbsp;mg of tenofovir disoproxil (as fumarate)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are croscarmellose sodium E468; hypromellose acetate succinate; magnesium stearate E470b; microcrystalline cellulose E460; silica, colloidal anhydrous E551; sodium stearyl fumarate. The tablets are film-coated with a coating material containing the following ingredients: carnauba wax E903, hypromellose E464; iron oxide yellow E172; lactose monohydrate; titanium dioxide E171; and triacetin E1518.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Delstrigo is available as a yellow, oval-shaped, film-coated tablet, and is debossed with the corporate logo and 776 on one side and plain on the other side.

The following pack sizes are available:

·                1 bottle with 30 film-coated tablets

·                90 film-coated tablets (3 bottles of 30 film-coated tablets)

Not all pack sizes may be available in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder: </strong></p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg 39</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>MSD International GmbH, Kilsheelan, Clonmel, Co. Tipperary, Ireland</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in June 2023


To report any side effect(s):

·            Saudi Arabia:

The National Pharmacovigilance Centre (NPC):

SFDA Call Center: 19999

E-mail: npc.drug@sfda.gov.sa

Website: https://ade.sfda.gov.sa

·            Other GCC States:

Please contact the relevant competent authority.



This is a Medicament

-        Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.

-        Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.

-        The doctor and the pharmacist are the experts in medicines, their benefits and risks.

-        Do not by yourself interrupt the period of treatment prescribed for you.

-        Do not repeat the same prescription without consulting your doctor.

-        Keep all medicaments out of reach of children.



Council of Arab Health

Ministers Union of Arab Pharmacists



This patient information leaflet is approved by the Saudi Food and Drug Authority






            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو </strong><strong>دلستريقو</strong></p><p dir="RTL">يستخدم دلستريقو لعلاج عدوى فيروس نقص المناعة البشرية (HIV). وهو ينتمي إلى مجموعة من الأدوية تُسمى &quot;الأدوية المضادة للفيروسات العكسية&quot;.</p><p dir="RTL">يحتوي دلستريقو على المواد الفعالة:</p><p dir="RTL">&bull; دورافيرين - مثبط إنزيم المُنتسِخة العكسية الغير نوكليوسيدي (NNRTI)</p><p dir="RTL">&bull; لاميفودين - مثبط إنزيم المنتسِخة العكسية التناظري للنيوكليوسيد (NRTI)</p><p dir="RTL">&bull; تينوفوفير ديسبروكسل - مثبط إنزيم المنتسِخة العكسية التناظري للنيوكليوسيد (NRTI)</p><p dir="RTL"><strong>ما هي </strong><strong>دواعي استخدام</strong><strong> </strong><strong>دلستريقو</strong></p><p dir="RTL">يُستخدم دلستريقو لعلاج عدوى فيروس نقص المناعة البشرية لدى &nbsp;البالغين و المراهقين من العمر 12 عامًا فما فوق و بوزن 35 كجم على الأقل. فيروس نقص المناعة البشرية هو الفيروس الذي يسبب الإيدز (&quot;متلازمة نقص المناعة المكتسب يجب ألّا تتناول &nbsp;دلستريقو إذا أخبرك طبيبك أنّ الفيروس المسبب للعدوى لديك مقاوم لأيّ من الأدوية الموجودة في دلستريقو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ألية عمل دلستريقو </strong></p><p dir="RTL">&nbsp;دلستريقو &nbsp;يعمل عن طريق منع فيروس نقص المناعة البشرية من صنع المزيد من الفيروسات في جسمك. سيساعد ذلك في:</p><p dir="RTL">&bull; تقليل كمية فيروس نقص المناعة البشرية في دمك (وهذا ما يسمى &quot;الحمل الفيروسي الخاص بك&quot;)</p><p dir="RTL">&bull; زيادة عدد خلايا الدم البيضاء التي تسمى &quot;CD4<sup>+ </sup>T&quot;. وهذا يمكن أن يجعل جهازك المناعي أقوى. وقد يقلل ذلك من خطر الوفاة المبكرة أو الإصابة بالعدوى الناجمة عن ضعف جهاز المناعة لديك. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم &nbsp;دلستريقو:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه دورافيرين أو لاميفودين أو تينوفوفير ديسبروكسل أو أي من المكونات الأخرى لهذا الدواء المدرجة في الفقرة رقم 6.</p><p dir="RTL">إذا كنت تتناول أيا من الأدوية التالية:</p><p dir="RTL">- كاربامازيبين، أوكسي كاربازيبين، فينوباربيتال، فينيتوين (أدوية للنوبات)</p><p dir="RTL">- ريفامبيسين، ريفابنتين (أدوية لمرض السل)</p><p dir="RTL">- نبتة سانت جون (<em>Hypericum perforatum</em>، وهو علاج عشبي يستخدم لعلاج الاكتئاب والقلق) أو المنتجات التي تحتوي عليه</p><p dir="RTL">- ميتوتان (دواء لعلاج السرطان)</p><p dir="RTL">- إنزالوتاميد (دواء لعلاج سرطان البروستاتا)</p><p dir="RTL">- لوماكافتور (دواء لعلاج التليف الكيسي)</p><p dir="RTL">لا تأخذ &nbsp;دلستريقو إذا كان أيّ مما سبق ينطبق عليك. تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل أن تأخذ دلستريقو إذا لم تكن متأكدا.</p><p dir="RTL">انظر أيضا القائمة في فقرة &quot;الأدوية&nbsp;الأخرى&nbsp;دلستريقو &quot;.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة &nbsp;قبل أن&nbsp; تأخذ دلستريقو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاقم عدوى التهاب الكبد (ب)</strong></p><p dir="RTL">إذا كان لديك عدوى بفيروس نقص المناعة البشرية والتهاب الكبد (ب) بنفس الوقت، فقد يتفاقم التهاب الكبد )ب( إذا توقفت عن تناول دلستريقو. قد تحتاج إلى فحوصات مخبرية للدم لعدة أشهر بعد إيقاف العلاج. ناقش علاج التهاب الكبد )ب( مع طبيبك.</p><p dir="RTL"><strong>مشاكل جديدة أو متفاقمة في الكِلَى، بما في ذلك الفشل الكلوي</strong></p><p dir="RTL">يمكن أن يحدث هذا في بعض الأشخاص الذين يتناولون دلستريقو. سيقوم الطبيب بإجراء فحوصات مخبرية للدم للتحقق من وظائف الكِلَى قبل وأثناء العلاج بدلستريقو.</p><p dir="RTL"><strong>مشاكل العظام</strong></p><p dir="RTL">يمكن أن يحدث هذا في بعض الأشخاص الذين يتناولون دلستريقو. تشمل مشاكل العظام:</p><p dir="RTL">ألم العظام، ولين العظام أو ترققها (مما قد يؤدي إلى حدوث كسور). قد يحدث ألم المفاصل أو العضلات أو ضعف العضلات أيضا. قد يحتاج طبيبك إلى إجراء فحوصات إضافية لعظامك.</p><p dir="RTL"><strong>متلازمة تنشيط المناعة</strong></p><p dir="RTL">يمكن أن يحدث هذا عند البدء في تناول أي دواء لفيروس نقص المناعة البشرية، بما في ذلك &nbsp;ديلستريغو. قد يصبح نظام المناعة لديك أقوى ويبدأ في مكافحة الالتهابات التي كانت كامنة في جسدك لفترة طويلة. أخبر طبيبك على الفور إذا بدأت تواجه أي أعراض جديدة بعد البدء في تناول دواء لفيروس نقص المناعة البشرية.</p><p dir="RTL">اضطرابات المناعة الذاتية (وهي حالة تحدث عندما يهاجم الجهاز المناعي أنسجة الجسم السليمة) قد تحدث أيضًا بعد البدء في تناول الأدوية لعلاج عدوى فيروس نقص المناعة البشرية. اضطرابات المناعة الذاتية قد تحدث بعد عدة أشهر من بدء العلاج. إذا لاحظت أي أعراض للعدوى أو أعراض أخرى مثل ضعف العضلات، وضعف في اليدين والقدمين والتحرك نحو جذع الجسم، خفقان، هزة أو فرط النشاط، يرجى إبلاغ الطبيب فوراً لطلب العلاج اللازم.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL"><strong>لا تعطِ هذا الدواء لأي طفل يقل عمره عن 12 عامًا أو </strong>بوزن أقل من 35 كجم. لم تتم دراسة دلستريقو لدى الأطفال الذين تقل أعمارهم عن 12 عامًا <strong>أو </strong>بوزن أقل من 35 كجم.</p><p dir="RTL"><strong>الأدوية الأخرى ودلستريقو </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول أو تناولت مؤخرا أو إذا كنت ستتناول أيّ أدوية أخرى فيما بعد. وذلك لأنّ الأدوية الأخرى قد تؤثر على آلية عمل دلستريقو أو قد يؤثر دلستريقو على الطريقة التي تعمل بها بعض الأدوية الأخرى.</p><p dir="RTL">هناك بعض الأدوية التي يجب ألّا تتناولها مع دلستريقو. انظر القائمة تحت فقرة &quot;لا تستخدم دلستريقو &quot;.</p><p dir="RTL">تحدث إلى طبيبك قبل تناول الأدوية التالية مع دلستريقو حيث قد يحتاج طبيبك إلى تغيير جرعة أدويتك:</p><p dir="RTL">&bull; بوسنتان (دواء لعلاج أمراض الرئة)</p><p dir="RTL">&bull; دابرافينب (دواء لعلاج سرطان الجلد)</p><p dir="RTL">&bull; ليسينوراد (دواء لعلاج النقرس)</p><p dir="RTL">&bull; مودافينيل (دواء لعلاج النعاس المفرط)</p><p dir="RTL">&bull; نافسيلّين (دواء لعلاج بعض أنواع العدوى البكتيرية)</p><p dir="RTL">&bull; ريفابوتين (دواء لعلاج بعض أنواع العدوى البكتيرية مثل السل)</p><p dir="RTL">&bull; تيلوتريستات إيثيل (دواء لعلاج الإسهال لدى الأشخاص المصابين بالمتلازمة السَّرَطاوية)</p><p dir="RTL">&bull; ثيوريدازين (دواء لعلاج الأمراض النفسية مثل الفِصام)</p><p dir="RTL">إذا قرر طبيبك أن تتناول هذه الأدوية مع دلستريقو فسوف يصف لك طبيبك قرص 100 مجم من دورافيرين يؤخذ يوميا، بعد حوالي 12 ساعة من تناولك جرعة دلستريقو .</p><p dir="RTL">قد يفحص الطبيب مستويات الدم لديك أو يراقب الأعراض الجانبية إذا كنت تتناول الأدوية التالية مع &nbsp;ديلستريغو:</p><p dir="RTL">&bull; سوفاسبوفير/ليديباسفير(أدوية مستخدمة لعلاج التهاب الكبد الوبائي سي)</p><p dir="RTL">&bull; سيروليمس (دواء يستخدم للتحكم في الاستجابة المناعية لجسمك بعد عملية زرع لعضو ما)</p><p dir="RTL">&bull; سوفاسبوفير/فيلباتاسفير (أدوية مستخدمة لعلاج التهاب الكبد الوبائي سي)</p><p dir="RTL">&bull; تاكروليمس (دواء يستخدم للسيطرة على الاستجابة المناعية لجسمك بعد عملية زرع لعضو ما)</p><p dir="RTL">&bull; الأدوية (عادة السوائل) التي تحتوي على السوربيتول والسكريات الكحولية الأخرى (مثل زايليتول أو مانيتول أو لاكتيتول أو مالتيتول) إذا ما تم تناولها بانتظام.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">تحدثي إلى طبيبكِ حول مخاطر وفوائد تناول دلستريقو إذا كنتِ حاملا أو ترضعين طبيعيا أو إذا كنتِ تعتقدين أنك قد تكونين حاملا أو تخططين للحمل. من الأفضل تجنب استخدام دلستريقو أثناء الحمل. وذلك لأنه لم يتم دراسته أثناء الحمل وليس معروفا ما إذا كان دلستريقو سيؤذي جنينك أم لا أثناء الحمل.</p><p dir="RTL">لا يُنصح بالرضاعة الطبيعية للنساء المصابات بفيروس نقص المناعة البشرية لأنّه يمكن نقل فيروس نقص المناعة البشرية إلى الأطفال من خلال حليب الثدي.</p><p dir="RTL">إذا كنت ترضعين طفلك رضاعة طبيعية، أو تفكرين في الرضاعة الطبيعية، يجب عليك مناقشة الأمر مع طبيبك في أقرب وقت ممكن.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">توخ الحذر عند القيادة أو ركوب الدراجة أو تشغيل الآلات إذا شعرت بالتعب أو الدوخة أو النعاس بعد تناول هذا الدواء.</p><p dir="RTL"><strong>أقراص دلستريقو تحتوي على اللاكتوز</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول هذا الدواء إذا سبق وأخبرك طبيب أنّ لديك عدم تحمل للّاكتوز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا حسب إرشادات الطبيب أو الصيدلي أو الممرض. استشر طبيبك أو الصيدلي أو الممرض إذا كنتَ غير متأكد. دلستريقو هو نظام كامل يؤخذ كقرص واحد لعلاج عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL"><strong>كم تبلغ الجرعة </strong></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد مرة واحدة في اليوم. إذا كنت تتناول أدوية معيّنة فقد يحتاج طبيبك إلى تغيير كمية دورافيرين التي تتناولها. راجع فقرة &quot;الأدوية الأخرى ودلستريقو&quot; للحصول على قائمة تلك الأدوية.</p><p dir="RTL"><strong>كيف تتناول هذا الدواء</strong></p><p dir="RTL">&bull; ابتلع القرص بالكامل (لا تسحقه أو تمضغه).</p><p dir="RTL">&bull; يمكن تناول هذا الدواء مع الطعام أو بين الوجبات.</p><p dir="RTL"><strong>إذا تناولت من دلستريقو أكثر مما يجب</strong></p><p dir="RTL">لا تتناول أكثر من الجرعة الموصى بها. اتصل بطبيبك إذا تناولت أكثر مما يطب عن طريق الخطأ.</p><p dir="RTL"><strong>إذا نسيت تناول إحدى جرعات دلستريقو </strong></p><p dir="RTL">&bull; من المهم ألّا تفوّت أو تتخطى أيّ جرعة من دلستريقو.</p><p dir="RTL">&bull; إذا نسيت جرعة فخذها حالما تتذكرها. ولكن إذا كانت الجرعة التالية مُستحقة في خلال 12&nbsp;ساعة<br />&nbsp; فتخطى الجرعة التي فاتتك وخذ الجرعة التالية في الوقت المعتاد. ثم تابع علاجك كالمعتاد.</p><p dir="RTL">&bull; لا تناول جرعتين من دلستريقو في نفس الوقت للتعويض عن جرعة منسية.</p><p dir="RTL">&bull; إذا لم تكن متأكدا مما يجب عليك فعله فاتصل بطبيبك أو الصيدلي.</p><p dir="RTL"><strong>إذا توقفت عن تناول دلستريقو</strong></p><p dir="RTL">لا تجعل دلستريقو ينفد لديك. أعد صرف وصفتك الطبية أو تحدث إلى طبيبك قبل نفاد دلستريقو من عندك.</p><p dir="RTL">إذا توقفت عن تناول دلستريقو فسوف يحتاج طبيبك إلى مراقبة وضعك الصحي مرارًا &nbsp;وإجراء فحوصات مخبرية للدم بانتظام لعدة أشهر لمراقبة عدوى فيروس نقص المناعة البشرية التي لديك. إذا كنت مُصابا بعدوى فيروس العوز المناعي البشري والتهاب الكبد الوبائي (ب) في نفس الوقت، فمن المهم بشكل خاص عدم إيقاف علاج دلستريقو دون التحدث إلى طبيبك أولا. فقد أظهرت فحوصات الدم أو أعراض المرض لدى بعض المرضى تفاقم التهاب الكبد (ب) لديهم بعد إيقاف عقار لاميفودين أو تينوفوفير ديسبروكسل (اثنان من الثلاثة مواد الفعالة في دواء دلستريقو). إذا تم إيقاف دلستريقو فقد يوصي طبيبك باستئناف علاج التهاب الكبد (ب). قد تحتاج إلى فحوصات مخبرية للدم للتأكد من فعالية وظيفة الكبد لمدة 4 أشهر بعد إيقاف العلاج. لا يُنصح بإيقاف العلاج لدى بعض المرضى الذين يعانون من أمراض الكبد المتقدمة أو تليف الكبد لأنّ هذا قد يؤدي إلى تفاقم التهاب الكبد (ب) والذي قد يكون مهددا للحياة.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع كل الأدوية، يُمكن أن يُسبّب هذا الدواء أعراضاً جانبية، على الرغم من أنها لا تحدث لدى جميع من يستخدمه.</p><p dir="RTL">لا تتوقف عن تناول هذا الدواء دون التحدث أولا مع طبيبك.</p><p dir="RTL"><strong>شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص:</p><p dir="RTL">&bull; أحلام غير طبيعية، صعوبة في النوم (الأرق)</p><p dir="RTL">&bull; صداع، دوخة، نعاس</p><p dir="RTL">&bull; سُعال وأعراض أنفية</p><p dir="RTL">&bull; الشعور بالمرض (غثيان) وإسهال وآلام في المعدة وتقيؤ وغازات (انتفاخ البطن)</p><p dir="RTL">&bull; تساقط الشعر، طفح جلدي</p><p dir="RTL">&bull; أعراض عضليّة (ألم، تصلّب)</p><p dir="RTL">&bull; الشعور بالتعب والحُمّى</p><p dir="RTL"><strong>وقد تُظهر فحوصات الدم المخبرية أيضا:</strong></p><p dir="RTL">&bull; زيادة مستويات إنزيمات الكبد (ALT)</p><p dir="RTL"><strong>غير شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص:</p><p dir="RTL">&bull; الكوابيس والاكتئاب والقلق والتهيج والارتباك والأفكار الانتحارية</p><p dir="RTL">&bull; صعوبة في التركيز، مشاكل في الذاكرة، وخز في اليدين والقدمين، وتصلّب العضلات، وتدني جودة&nbsp; لنوم</p><p dir="RTL">&bull; ارتفاع ضغط الدم.</p><p dir="RTL">&bull; إمساك، أو إنزعاج في المعدة، أو تورم أو معدة منتفخة (انتفاخ البطن)، وعسر الهضم، وبراز رخو، وتشنجات المعدة، وحركات الأمعاء المتكررة، والتهاب البنكرياس (مما يسبب آلام في المعدة، والتقيؤ)</p><p dir="RTL">&bull; حكة</p><p dir="RTL">&bull; آلام المفاصل، وتكسّر الأنسجة العضلية، وضعف العضلات</p><p dir="RTL">&bull; الشعور بالضعف والشعور العام بالتوعك</p><p dir="RTL"><strong>وقد تُظهر فحوصات الدم المخبرية أيضا:</strong></p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء في دمك (قلة العدلات)</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء في دمك (فقر الدم)</p><p dir="RTL">&bull; انخفاض مستويات الصفائح الدموية في دمك (قد تنزف بسهولة أكبر)</p><p dir="RTL">&bull; انخفاض مستويات الفوسفات</p><p dir="RTL">&bull; انخفاض مستويات البوتاسيوم في دمك</p><p dir="RTL">&bull; زيادة مستويات الكرياتينين في دمك</p><p dir="RTL">&bull; زيادة مستويات إنزيمات الكبد (AST)</p><p dir="RTL">&bull; زيادة مستويات اللّيباز</p><p dir="RTL">&bull; زيادة مستويات الأميلاز</p><p dir="RTL">&bull; انخفاض مستويات الهيموغلوبين</p><p dir="RTL">قد تحدث آلام العضلات وضعف العضلات والنقصان في البوتاسيوم أو الفوسفات في الدم بسبب تلف خلايا الكِلَى النُبيبيّة.</p><p dir="RTL"><strong>نادرة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص</p><p dir="RTL">&bull; العدوانية، والهلوسة، وصعوبة التكيف مع التغيرات، وتغيرات المزاج، والمشي أثناء النوم</p><p dir="RTL">&bull; صعوبة في التنفس، تضخم اللوزتين</p><p dir="RTL">&bull; الشعور بعدم التغوط الكامل</p><p dir="RTL">&bull; تضخم الكبد أو الكبد الدهني، اصفرار الجلد أو العينين، ألم في البطن بسبب التهاب الكبد.</p><p dir="RTL">&bull; التهاب الجلد بسبب الحساسية، احمرار الخدين أو الأنف أو الذقن أو الجبين، أو نتوءات أو بثور على الوجه أو تورم الوجه أو الشفتين أو اللسان أو الحلق.</p><p dir="RTL">&bull; ضعف العضلات وضعف العظام (مع ألم في العظام وأحيانا ما يؤدي إلى كسور)</p><p dir="RTL">&bull; تلف الكِلَى، حصى الكِلَى، الفشل الكلوي، تلف خلايا الكِلَى النُبيبيّة، إصابة الكِلَى، إخراج الكثير من البول والشعور بالعطش</p><p dir="RTL">&bull; ألم في الصدر، والشعور بالبرد والألم والعطش</p><p dir="RTL"><strong>قد تُظهر فحوصات الدم المخبرية أيضا:</strong></p><p dir="RTL">&bull; انخفاض مستويات المغنيسيوم</p><p dir="RTL">&bull; الحُماض اللّاكتيكي (ارتفاع حمض اللّاكتيك في الدم)</p><p dir="RTL">&bull; زيادة مستويات إنزيم فسفوكيناز الكرياتين</p><p dir="RTL"><strong>نادرة جدًا:</strong> قد تؤثر على ما يصل إلى 1 من كل 10000 شخص</p><p dir="RTL"><strong>قد تُظهر فحوصات الدم المخبرية أيضا:</strong></p><p dir="RTL">&nbsp;&bull; فشل نخاع العظم في إنتاج خلايا دم حمراء جديدة (عدم تنسُّج الخلايا الحمراء الصّرفة)</p><p dir="RTL">الإبلاغ عن الأعراض الجانبية:</p><p dir="RTL">إذا أُصبت ﺑﺄي من الأعراض الجانبية، فينبغي استشارة الطبيب أو الصيدلي أو الممرض. يشمل هذا أي أعراض جانبية ممكنة ليست مذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبية عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء السعودية&quot;.</p><p dir="RTL">من خلال إبلاغك عن الأعراض الجانبية، يُمكنك المُساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p dir="RTL">&bull; يُحفظ هذا الدواء بعيدا عن عن أنظار ومُتناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على العبوة بعد كلمة &quot;EXP.&quot;</p><p dir="RTL">&bull; تحتوي العبوة على مُجفِّف (مغلف مانع الرطوبة) يحمي الأقراص من الرطوبة. قد يكون هناك أكثر من مُجفِّف واحد في العبوة. اترك المُجفِّف داخل العبوة ولا تتخلص منه حتى تنتهي من تناول الدواء بالكامل.</p><p dir="RTL">&bull; احتفظ بالعبوة مغلقة بإحكام من أجل حماية الدواء من الرطوبة.</p><p dir="RTL">&bull; لا تتخلّص من أيّ أدوية عن طريق مياه الصرف الصّحي أو الِنفايات المنزلية. اسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعد بحاجة إليها. تُساعد هذه التدابير في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي دلستريقو </strong></p><p dir="RTL">&bull; <strong>المواد الفعالة هي:</strong> 100 ملغم من دورافيرين ، 300 ملغم من لاميفودين و 245 ملغم من تينوفوفير ديسبروكسل</p><p dir="RTL">&nbsp;(على شكل فومارات)</p><p dir="RTL">&bull; <strong>المكونات الأخرى هي: </strong>صوديوم كروسكارميلوز (E468)؛ سَكْسِينات أسيتات هيبروميلوز؛ ستيرات المغنيسيوم (E470b)؛ سِلّولوز بِلّوري مِكْرَوي (E460)؛ سيليكا غرويه لا مائية (E551)؛ فومارات ستياريل الصوديوم.</p><p dir="RTL">الأقراص مغلفة بغشاء رقيق يحتوي على المكونات التالية: شمع الكارنوبا (E903)؛ هيبروميلوز (E464)؛ أكسيد الحديد الأصفر (E172)؛ مونوهيدرات اللاكتوز؛ ثاني أكسيد التيتانيوم (E171) وثلاثي الأستين (E1518).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو دلستريقو ومحتويات العبوة</strong></p><p dir="RTL">يتوفر دلستريقو على شكل أقراص صفراء بيضاوية الشكل ومغلفة بغشاء رقيق، ومحفور عليها شعار الشركة و 776 على جانب واحد أمّا الجانب الآخر فلا شيء عليه.</p><p dir="RTL"><strong>تتوفر أحجام العبوات التالية:</strong></p><p dir="RTL">&bull; قارورة واحدة تحتوي على 30 قرصا مغلفة</p><p dir="RTL">&bull; 90 قرص مغلف (3 عبوات كل عبوة تحتوي على 30 قرص مغلف)</p><p dir="RTL">&nbsp;قد لا تتوفر جميع أحجام العبوات في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق</strong></p><p dir="RTL">ميرك شارب ودوم بي. في.</p><p dir="RTL">واردرويج 39</p><p dir="RTL">٢٠٣١ بي إن هارلم</p><p dir="RTL">هولندا</p><p dir="RTL">الشركة الصّانِعة</p><p dir="RTL">شركة إم إس دي الدولية جي إم بي إتش، كيلشيلان، كلوميل، شركه تيبيراري، إيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ: يونيو 2023.

للإبلاغ عن أيّ أعراض جانبية:
• المملكة العربية السعودية:
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
• دول مجلس التعاون الخليجي الأخرى:
يرجى الاتصال بالجهة المختصة ذات الصلة.

(هذا دواء)
-	الدّواء مستحضر يُؤثِّر على صحتك وتناوله خِلافا للتّعليمات يُعَرِّضُك للخطر.
-	اتّبع بدقة وصفة الطّبِيب وطريقة الاستعمال وتعليمات الصيدلي الذي صرف لك هذا الدّواء.
-	الطّبِيب والصيدلي هما الخبيران بالدّواء وبنفعه وضرره.
-	لا تقطع مُدّة العلاج المحُدّدة لك من تِلْقَاء نفسك.
-	لا تُكرِّر صرف الدّواء بدون استشارة الطّبِيب.
-	احفظ الأدوية بعيدا عن متناول أيدي الأطفال.
مجلس وزراء الصِّحة العرب
واتِّحاد الصيادلة العرب
تمت الموافقة على نشرة معلومات المريض هذه من قبل الهيئة السعودية للغذاء والدواء

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Delstrigo 100 mg/300 mg/245 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each film-coated tablet contains 100 mg of doravirine, 300 mg of lamivudine (3TC), and 245 mg of tenofovir disoproxil as tenofovir disoproxil fumarate (TDF).

Excipient with known effect

Each film-coated tablet contains 8.6 mg lactose (as monohydrate).

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Yellow, oval-shaped, tablet of dimensions 21.59 mm x 11.30 mm, debossed with the corporate logo and 776 on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Delstrigo is indicated for the treatment of adults infected with human immunodeficiency virus&nbsp;type&nbsp;1 (HIV‑1) without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitors (NNRTI) class, lamivudine, or tenofovir (see sections&nbsp;4.4 and&nbsp;5.1).</p><p>&nbsp;</p><p>Delstrigo is also indicated for the treatment of adolescents aged 12&nbsp;years and older weighing at least 35&nbsp;kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil (see sections&nbsp;4.4 and&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The recommended dose of Delstrigo is one 100/300/245&nbsp;mg tablet taken orally once daily with or without food.</p><p>&nbsp;</p><p><em>Dose adjustment</em></p><p>If Delstrigo is co-administered with rifabutin, the doravirine dose should be increased to 100&nbsp;mg twice daily. This is achieved by adding one 100&nbsp;mg tablet of doravirine (as a single agent), to be taken approximately 12&nbsp;hours apart from the dose of Delstrigo (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Co-administration of doravirine with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected. If co-administration with other moderate CYP3A inducers (e.g., dabrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, one 100&nbsp;mg tablet of doravirine should be taken daily, approximately 12&nbsp;hours after the dose of Delstrigo (see section&nbsp;4.5).</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>If the patient misses a dose of Delstrigo within 12&nbsp;hours of the time it is usually taken, the patient should take Delstrigo as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Delstrigo by more than 12&nbsp;hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not take 2&nbsp;doses at one time.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>There are limited data available on the use of doravirine, lamivudine, and tenofovir disoproxil in patients aged 65&nbsp;years and over. There is no evidence that elderly patients require a different dose than younger adult patients (see section&nbsp;5.2). Special care is advised in this age group due to age associated changes such as decreases in renal function (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of Delstrigo is required in patients with estimated creatinine clearance (CrCl) &ge;&nbsp;50&nbsp;mL/min.</p><p><strong>&nbsp;</strong></p><p>Delstrigo should not be initiated in patients with estimated CrCl &lt;&nbsp;50&nbsp;mL/min (see sections&nbsp;4.4 and&nbsp;5.2). Delstrigo should be discontinued if estimated CrCl declines below 50&nbsp;mL/min (see section&nbsp;4.4). Patients with moderate or severe renal impairment require a dose interval adjustment of lamivudine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections&nbsp;4.4 and&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of doravirine/lamivudine/tenofovir disoproxil is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Doravirine has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). It is not known whether the exposure to doravirine will increase in patients with severe hepatic impairment. Therefore, caution is advised when doravirine/lamivudine/tenofovir disoproxil is administered to patients with severe hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Safety and efficacy of Delstrigo in children aged less than 12&nbsp;years or weighing less than 35&nbsp;kg have not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Delstrigo must be taken orally, once daily with or without food and swallowed whole (see section&nbsp;5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of Delstrigo (see sections 4.4 and 4.5). These medicinal products include, but are not limited to the following:
•	carbamazepine, oxcarbazepine, phenobarbital, phenytoin
•	rifampicin, rifapentine
•	St. John’s wort (Hypericum perforatum)
•	mitotane
•	enzalutamide
•	lumacaftor
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>NNRTI substitutions and use of doravirine</u></p><p><u>&nbsp;</u></p><p>Doravirine has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy. NNRTI-associated mutations detected at screening were part of exclusion criteria in the Phase&nbsp;2b/3-studies. A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established (see section&nbsp;5.1). There is not sufficient clinical evidence to support the use of doravirine in patients infected with HIV‑1 with evidence of resistance to the NNRTI class.</p><p>&nbsp;</p><p><u>Severe acute exacerbation of hepatitis B in patients co-infected with HIV</u><u>‑</u><u>1 and HBV</u></p><p>&nbsp;</p><p>All patients with HIV‑1 should be tested for the presence of hepatitis B virus (HBV) before initiating antiretroviral therapy.</p><p>&nbsp;</p><p>Severe acute exacerbations of hepatitis B (e.g., liver decompensated and liver failure) have been reported in patients who are co-infected with HIV‑1 and HBV, and have discontinued lamivudine or tenofovir disoproxil, two of the components of Delstrigo. Patients who are co-infected with HIV‑1 and HBV should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with Delstrigo. If appropriate, initiation of anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.</p><p>&nbsp;</p><p><u>New onset or worsening renal impairment</u></p><p>&nbsp;</p><p>Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphataemia), has been reported with the use of tenofovir disoproxil, a component of Delstrigo<em>.</em></p><p>&nbsp;</p><p>Delstrigo should be avoided with concurrent or recent use of nephrotoxic medicinal products (e.g., high-dose or multiple nonsteroidal anti-inflammatory medicinal products [NSAIDs]) (see section&nbsp;4.5). Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in HIV‑infected patients with risk factors for renal dysfunction who appeared stable on tenofovir disoproxil. Some patients required hospitalisation and renal replacement therapy. Alternatives to NSAIDs should be considered, if needed, in patients at risk for renal dysfunction.</p><p>&nbsp;</p><p>Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in at risk patients.</p><p>&nbsp;</p><p>It is recommended that estimated CrCl be assessed in all patients prior to initiating therapy and as clinically appropriate during therapy with Delstrigo. In patients at risk of renal dysfunction, including patients who have previously experienced renal events while receiving adefovir dipivoxil, it is recommended that estimated CrCl, serum phosphorus, urine glucose, and urine protein be assessed prior to initiation of Delstrigo and more frequent renal function monitoring should be assessed as appropriate per the patient&rsquo;s medical condition during Delstrigo therapy.</p><p>&nbsp;</p><p>Lamivudine and tenofovir disoproxil are primarily excreted by the kidney. Delstrigo should be discontinued if estimated CrCl declines below 50&nbsp;mL/min as dose interval adjustment required for lamivudine and tenofovir disoproxil cannot be achieved with the fixed dose combination tablet (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Bone loss and mineralisation defects</u></p><p>&nbsp;</p><p><em>Bone mineral density</em></p><p>In clinical trials in HIV‑1 infected adults, tenofovir disoproxil was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving tenofovir disoproxil. In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor.</p><p>&nbsp;</p><p>Bone abnormalities (infrequently contributing to fractures) may be associated with proximal renal tubulopathy.</p><p>&nbsp;</p><p>The effects of tenofovir disoproxil associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Assessment of BMD should be considered for HIV‑1 infected adult patients who have a history of pathologic bone fracture or other risk factors for osteoporosis or bone loss. Although the effect of supplementation with calcium and Vitamin D was not studied, such supplementation may be beneficial in all patients. If bone abnormalities are suspected, then appropriate consultation should be obtained.</p><p>&nbsp;</p><p><em>Mineralisation defects</em></p><p>Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir disoproxil . Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy. Hypophosphataemia and osteomalacia secondary to proximal renal tubulopathy should be considered in patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms while receiving products containing tenofovir disoproxil (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Co-administration with other antiviral products</u></p><p>&nbsp;</p><p>Doravirine/lamivudine/tenofovir disoproxil must not be co-administered with other medicinal products containing lamivudine, or with medicinal products containing tenofovir disoproxil, or tenofovir alafenamide, or with adefovir dipivoxil (see section&nbsp;4.5). Doravirine/lamivudine/tenofovir disoproxil should not be administered with doravirine unless needed for dose adjustment (e.g., with rifabutin) (see sections&nbsp;4.2 and&nbsp;4.5).</p><p>&nbsp;</p><p><u>Use with CYP3A inducers</u></p><p>&nbsp;</p><p>Caution should be given to prescribing doravirine with medicinal products that may reduce the exposure of doravirine (see sections&nbsp;4.3 and&nbsp;4.5).</p><p>&nbsp;</p><p><u>Immune reactivation syndrome</u></p><p>&nbsp;</p><p>Immune reactivation syndrome has been reported in patients treated with combination antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as <em>Mycobacterium avium</em> infection, cytomegalovirus, <em>Pneumocystis jirovecii</em> pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.</p><p>&nbsp;</p><p>Autoimmune disorders (such as Graves&rsquo; disease, autoimmune hepatitis, polymyositis, and Guillain-Barr&eacute; syndrome) have also been reported to occur in the setting of immune reactivation; however, the time to onset is more variable and can occur many months after initiation of treatment.</p><p>&nbsp;</p><p><u>Lactose</u></p><p>&nbsp;</p><p>Delstrigo contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Delstrigo is a complete regimen for the treatment of HIV‑1 infection; therefore, Delstrigo should not be administered with other antiretroviral medicinal products. Information regarding potential medicinal product interactions with other antiretroviral medicinal products is not provided.</p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>Delstrigo contains doravirine, lamivudine, and tenofovir disoproxil, therefore any interactions identified for these individually are relevant to Delstrigo and are presented in Table&nbsp;1.</p><p><u>&nbsp;</u></p><p><u>Effects of other medicinal products on doravirine, lamivudine, and tenofovir</u><u> </u><u>disoproxil</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A are expected to affect the clearance of doravirine (see section&nbsp;5.2). Doravirine/lamivudine/tenofovir disoproxil should not be co-administered with medicinal products that are strong CYP3A enzyme inducers as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of doravirine/lamivudine/tenofovir disoproxil (see sections&nbsp;4.3 and&nbsp;5.2).</p><p><em><u>&nbsp;</u></em></p><p>Co-administration with the moderate CYP3A inducer rifabutin decreased doravirine concentrations (see Table&nbsp;1). When Delstrigo is co-administered with rifabutin, a 100&nbsp;mg dose of doravirine should be given daily, approximately 12&nbsp;hours after doravirine/lamivudine/tenofovir disoproxil dose (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Co-administration of doravirine/lamivudine/tenofovir disoproxil with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected. If co-administration with other moderate CYP3A inducers (e.g., debrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, a 100&nbsp;mg dose of doravirine should be administered daily, approximately 12&nbsp;hours after the administration of doravirine/lamivudine/tenofovir disoproxil dose (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Co-administration of doravirine/lamivudine/tenofovir disproxil and medicinal products that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. However, no dose adjustment is needed when doravirine is co-administered with CYP3A inhibitors.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Because lamivudine is primarily eliminated by the kidneys through a combination of glomerular filtration and active tubular secretion (see section&nbsp;5.2), co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products that reduce renal function or compete for active tubular secretion may increase serum concentrations of lamivudine.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Because tenofovir is primarily eliminated by the kidneys through a combination of glomerular filtration and active tubular secretion (see section&nbsp;5.2), co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products that reduce renal function or compete for active tubular secretion via OAT1, OAT3 or MRP4 may increase serum concentrations of tenofovir.</p><p><u>&nbsp;</u></p><p>Due to the tenofovir disoproxil component of doravirine/lamivudine/tenofovir disoproxil, use of the product should be avoided with concurrent or recent use of nephrotoxic medicinal products. Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs (see section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p><u>Effects of doravirine, lamivudine, and tenofovir disoproxil on other medicinal products</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine at a dose of 100&nbsp;mg once daily is not likely to have a clinically relevant effect on the plasma concentrations of medicinal products that are dependent on transport proteins for absorption and/or elimination or that are metabolised by CYP enzymes.</p><p>&nbsp;</p><p>However, co-administration of doravirine and the sensitive CYP3A substrate midazolam resulted in a 18&nbsp;% decrease in midazolam exposure, suggesting that doravirine may be a weak CYP3A inducer. Therefore, caution should be used when co-administering doravirine with medicinal products that are sensitive CYP3A substrates that also have a narrow therapeutic window (e.g., tacrolimus and sirolimus).</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Lamivudine does not inhibit or induce CYP enzymes.</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>Based on the results of <em>in vitro</em> experiments and the known elimination pathway of tenofovir, the potential for CYP-mediated interactions involving tenofovir with other medicinal products is low.</p><p><u>&nbsp;</u></p><p><u>Interaction table</u></p><p>&nbsp;</p><p>Table 1 shows the established and other potential medicinal product interactions with the individual components of Delstrigo but is not all inclusive (increase is indicated as &uarr;, decrease is indicated as &macr;, and no change as &laquo;). For potential medicinal product interactions with tenofovir disoproxil or lamivudine, (see sections&nbsp;4.4 and&nbsp;5.2).</p><p>&nbsp;</p><p><strong>Table 1: Interactions between the individual components of Delstrigo</strong><strong> and other medicinal products</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><thead><tr><td><p><strong>Medicinal </strong><strong>product</strong><strong> by </strong><strong>therapeutic area</strong></p></td><td><p><strong>Effects on </strong><strong>medicinal product levels</strong></p><p><strong>geometric mean ratio</strong><strong> (90</strong><strong>&nbsp;</strong><strong>% CI)*</strong></p></td><td><p><strong>Recommendation </strong><strong>concerning</strong></p><p><strong>co</strong><strong>-administration with doravirine/lamivudine/</strong><strong>tenofovir</strong><strong> disoproxil</strong></p></td></tr></thead><tbody><tr><td colspan="3"><p>Acid-reducing agents</p></td></tr><tr><td><p>antacid (aluminium and magnesium hydroxide oral suspension)</p><p>(20&nbsp;mL SD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&laquo; doravirine</p><p>AUC 1.01 (0.92, 1.11)</p><p>C<sub>max</sub> 0.86 (0.74, 1.01)</p><p>C<sub>24</sub> 1.03 (0.94, 1.12)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>pantoprazole</p><p>(40&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&macr; doravirine</p><p>AUC 0.83 (0.76, 0.91)</p><p>C<sub>max</sub> 0.88 (0.76, 1.01)</p><p>C<sub>24</sub> 0.84 (0.77, 0.92)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>omeprazole</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Angiotensin converting enzyme inhibitors</p></td></tr><tr><td><p>lisinopril</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; lisinopril</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Antiandrogens</p></td></tr><tr><td><p>enzalutamide</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Antibiotics</p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td><p>nafcillin</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, approximately12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Anticonvulsants</p></td></tr><tr><td><p>carbamazepine</p><p>oxcarbazepine</p><p>phenobarbital</p><p>phenytoin</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>Antidiabetics</p></td></tr><tr><td><p>metformin</p><p>(1&nbsp;000&nbsp;mg SD,</p><p>doravirine 100&nbsp;mg QD)</p></td><td><p>&laquo; metformin</p><p>AUC 0.94 (0.88, 1.00)</p><p>C<sub>max</sub> 0.94 (0.86, 1.03)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>canagliflozin</p><p>liraglutide</p><p>sitagliptin</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; canagliflozin</p><p>&laquo; liraglutide</p><p>&laquo; sitagliptin</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Antidiarrhoeals</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>telotristat ethyl</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, 12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Antigout and uricosuric agents</p></td></tr><tr><td><p>lesinurad</p><p>&nbsp;</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, approximately 12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Antimycobacterials</p></td></tr><tr><td><p>Single dose rifampicin</p><p>(600&nbsp;mg SD,</p><p>doravirine 100&nbsp;mg SD)</p><p>&nbsp;</p><p>Multiple dose rifampicin</p><p>(600&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&laquo; doravirine</p><p>AUC 0.91 (0.78, 1.06)</p><p>C<sub>max</sub> 1.40 (1.21, 1.63)</p><p>C<sub>24</sub> 0.90 (0.80, 1.01)</p><p>&nbsp;</p><p>&macr; doravirine</p><p>AUC 0.12 (0.10, 0.15)</p><p>C<sub>max</sub> 0.43 (0.35, 0.52)</p><p>C<sub>24</sub> 0.03 (0.02, 0.04)</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td><p>rifapentine</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td><p>rifabutin</p><p>(300&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&macr; doravirine</p><p>AUC 0.50 (0.45, 0.55)</p><p>C<sub>max</sub> 0.99 (0.85, 1.15)</p><p>C<sub>24</sub> 0.32 (0.28, 0.35)</p><p>(Induction of CYP3A)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>If doravirine/ lamivudine/ tenofovir disoproxil is co-administered with rifabutin, a 100&nbsp;mg dose of doravirine should be taken daily, approximately 12&nbsp;h after dose of doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p></td></tr><tr><td colspan="3"><p>Antineoplastics</p></td></tr><tr><td><p>mitotane</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>Antipsychotics</p></td></tr><tr><td><p>&nbsp;</p><p>thioridazine</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, approximately 12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Azole antifungal agents</p></td></tr><tr><td><p>ketoconazole</p><p>(400&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&shy; doravirine</p><p>AUC 3.06 (2.85, 3.29)</p><p>C<sub>max</sub> 1.25 (1.05, 1.49)</p><p>C<sub>24</sub> 2.75 (2.54, 2.98)</p><p>(Inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>fluconazole</p><p>itraconazole</p><p>posaconazole</p><p>voriconazole</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Calcium channel blockers</p></td></tr><tr><td><p>diltiazem</p><p>verapamil</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Cystic fibrosis treatment</p></td></tr><tr><td><p>lumacaftor</p><p>&nbsp;</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>Endothelin receptor antagonists</p></td></tr><tr><td><p>&nbsp;</p><p>bosentan</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, approximately12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Hepatitis C antiviral agents</p></td></tr><tr><td><p>elbasvir + grazoprevir</p><p>(50&nbsp;mg elbasvir QD + 200&nbsp;mg grazoprevir QD,</p><p>doravirine 100&nbsp;mg QD)</p></td><td><p>&shy; doravirine</p><p>AUC 1.56 (1.45, 1.68)</p><p>C<sub>max </sub>1.41 (1.25, 1.58)</p><p>C<sub>24</sub> 1.61 (1.45, 1.79)</p><p>(Inhibition of CYP3A)</p><p>&nbsp;</p><p>&laquo; elbasvir</p><p>AUC 0.96 (0.90, 1.02)</p><p>C<sub>max </sub>0.96 (0.91, 1.01)</p><p>C<sub>24</sub> 0.96 (0.89, 1.04)</p><p>&nbsp;</p><p>&laquo; grazoprevir</p><p>AUC 1.07 (0.94, 1.23)</p><p>C<sub>max</sub> 1.22 (1.01, 1.47)</p><p>C<sub>24</sub> 0.90 (0.83, 0.96)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ledipasvir + sofosbuvir</p><p>(90&nbsp;mg ledipasvir SD + 400&nbsp;mg sofosbuvir SD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&uarr; doravirine</p><p>AUC 1.15 (1.07, 1.24)</p><p>C<sub>max</sub> 1.11 (0.97, 1.27)</p><p>C<sub>24</sub> 1.24 (1.13, 1.36)</p><p>&nbsp;</p><p>&laquo; ledipasvir</p><p>AUC 0.92 (0.80, 1.06)</p><p>C<sub>max</sub> 0.91 (0.80, 1.02)</p><p>&nbsp;</p><p>&laquo; sofosbuvir</p><p>AUC 1.04 (0.91, 1.18)</p><p>C<sub>max</sub> 0.89 (0.79, 1.00)</p><p>&nbsp;</p><p>&laquo; GS-331007</p><p>AUC 1.03 (0.98, 1.09)</p><p>C<sub>max</sub> 1.03 (0.97, 1.09)</p><p>&nbsp;</p><p>Expected:</p><p>&uarr; tenofovir</p></td><td><p>Patients receiving doravirine/lamivudine/tenofovirdisoproxil concomitantly with ledipasvir/sofosbuvir</p><p>should be monitored for adverse reactions associated with tenofovir disoproxil.</p></td></tr><tr><td><p>sofosbuvir/velpatasvir</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p><p>&uarr; tenofovir</p></td><td><p>Patients receiving doravirine/lamivudine/tenofovir disoproxil concomitantly with sofosbuvir/velpatasvir should be monitored for adverse reactions associated with tenofovir disoproxil.</p></td></tr><tr><td><p>sofosbuvir</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>daclatasvir</p><p>&nbsp;</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ombitasvir/paritaprevir/ ritonavir and dasabuvir +/- ritonavir</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A due to ritonavir)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>dasabuvir</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>glecaprevir, pibrentasvir</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ribavirin</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Herbal supplements</p></td></tr><tr><td><p>St. John&rsquo;s wort</p><p>(<em>Hypericum perforatum)</em></p><p>&nbsp;</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>HIV antiviral agents</p></td></tr><tr><td><p>tenofovir disoproxil</p><p>(300&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&laquo; doravirine</p><p>AUC 0.95 (0.80, 1.12)</p><p>C<sub>max</sub> 0.80 (0.64, 1.01)</p><p>C<sub>24</sub> 0.94 (0.78, 1.12)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>lamivudine + tenofovir disoproxil</p><p>(300&nbsp;mg lamivudine SD + 245&nbsp;mg tenofovir disoproxil SD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td><p>&laquo; doravirine</p><p>AUC 0.96 (0.87, 1.06)</p><p>C<sub>max </sub>0.97 (0.88, 1.07)</p><p>C<sub>24</sub> 0.94 (0.83, 1.06)</p><p>&nbsp;</p><p>&laquo;lamivudine</p><p>AUC 0.94 (0.88, 1.00)</p><p>C<sub>max</sub> 0.92 (0.81, 1.05)</p><p>&nbsp;</p><p>&laquo; tenofovir</p><p>AUC 1.11 (0.97, 1.28)</p><p>C<sub>max</sub> 1.17 (0.96, 1.42)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Immunosuppressants</p></td></tr><tr><td><p>tacrolimus</p><p>sirolimus</p><p>&nbsp;</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p><p>&darr; tacrolimus, sirolimus</p><p>(Induction of CYP3A)</p></td><td><p>Monitor blood concentrations of tacrolimus and sirolimus as the dose of these agents may need to be adjusted.</p></td></tr><tr><td colspan="3"><p>Kinase inhibitors</p></td></tr><tr><td><p>&nbsp;</p><p>dabrafenib</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, approximately 12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Miscellaneous</p></td></tr><tr><td><p>sorbitol solution (3.2&nbsp;g, 10.2&nbsp;g, 13.4&nbsp;g)/lamivudine</p></td><td style="vertical-align:top"><p>Single dose lamivudine oral solution 300&nbsp;mg</p><p>&nbsp;</p><p>lamivudine</p><p>AUC &macr; 14&nbsp;%; 32&nbsp;%; 35&nbsp;%</p><p>C<sub>max</sub> &macr; 28&nbsp;%; 52&nbsp;%; 55&nbsp;%</p></td><td><p>When possible, avoid chronic co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products containing sorbitol or other osmotic acting poly-alcohols (e.g., xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV‑1 viral load when chronic co-administration cannot be avoided.</p></td></tr><tr><td colspan="3"><p>Opioid analgesics</p></td></tr><tr><td><p>methadone</p><p>(20-200&nbsp;mg QD individualised dose,</p><p>doravirine 100&nbsp;mg QD)</p></td><td><p>&macr; doravirine</p><p>&nbsp;</p><p>AUC 0.74 (0.61, 0.90)</p><p>C<sub>max</sub> 0.76 (0.63, 0.91)</p><p>C<sub>24</sub> 0.80 (0.63, 1.03)</p><p>&nbsp;</p><p>&laquo; R-methadone</p><p>AUC 0.95 (0.90, 1.01)</p><p>C<sub>max</sub> 0.98 (0.93, 1.03)</p><p>C<sub>24</sub> 0.95 (0.88, 1.03)</p><p>&nbsp;</p><p>&laquo; S-methadone</p><p>AUC 0.98 (0.90, 1.06)</p><p>C<sub>max</sub> 0.97 (0.91, 1.04)</p><p>C<sub>24</sub> 0.97 (0.86, 1.10)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>buprenorphine</p><p>naloxone</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; buprenorphine</p><p>&laquo; naloxone</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Oral contraceptives</p></td></tr><tr><td><p>0.03&nbsp;mg ethinyl oestradiol/ 0.15&nbsp;mg levonorgestrel SD,</p><p>doravirine 100&nbsp;mg QD</p></td><td><p>&laquo; ethinyl oestradiol</p><p>AUC 0.98 (0.94, 1.03)</p><p>C<sub>max</sub> 0.83 (0.80, 0.87)</p><p>&nbsp;</p><p>&shy; levonorgestrel</p><p>AUC 1.21 (1.14, 1.28)</p><p>C<sub>max</sub> 0.96 (0.88, 1.05)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>norgestimate/ethinyl oestradiol</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; norgestimate/ethinyl oestradiol</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Psychostimulants</p></td></tr><tr><td><p>&nbsp;</p><p>modafinil</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, a 100&nbsp;mg dose of doravirine should be taken daily, approximately12&nbsp;h after the dose of doravirine/lamivudine/tenofovir disoproxil.</p></td></tr><tr><td colspan="3"><p>Sedatives/Hypnotics</p></td></tr><tr><td><p>midazolam</p><p>(2&nbsp;mg SD,</p><p>doravirine 120&nbsp;mg QD)</p></td><td><p>&macr; midazolam</p><p>AUC 0.82 (0.70, 0.97)</p><p>C<sub>max</sub> 1.02 (0.81, 1.28)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Statins</p></td></tr><tr><td><p>atorvastatin</p><p>(20&nbsp;mg SD,</p><p>doravirine 100&nbsp;mg QD)</p></td><td><p>&laquo; atorvastatin</p><p>AUC 0.98 (0.90, 1.06)</p><p>C<sub>max</sub> 0.67 (0.52, 0.85)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>rosuvastatin</p><p>simvastatin</p></td><td><p>Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; rosuvastatin</p><p>&laquo; simvastatin</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>&shy; = increase, &darr;&nbsp;=&nbsp;decrease, &harr;&nbsp;=&nbsp;no change</p><p>CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily</p><p>*AUC<sub>0</sub><sub>-</sub><sub>&yen;</sub> for single dose, AUC<sub>0-24 </sub>for once daily.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of doravirine in pregnant women. A large amount of data on pregnant women (more than 3&nbsp;000 outcomes from first trimester) taking the individual active component lamivudine in combination with other antiretrovirals indicates no malformative toxicity. A moderate amount of data on pregnant women (between 300-1&nbsp;000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with tenofovir disoproxil.</p><p>&nbsp;</p><p><em>Antiretroviral pregnancy registry</em></p><p>To monitor maternal-foetal outcomes in patients exposed to antiretroviral medicinal products while pregnant, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients in this registry.</p><p>&nbsp;</p><p>Animal studies with doravirine do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Animal studies with tenofovir disoproxil do not indicate direct or indirect harmful effects of tenofovir disoproxil with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section&nbsp;5.3). Placental transfer of lamivudine has been shown to occur in humans. Lamivudine may inhibit cellular DNA replication (see section&nbsp;5.3). The clinical relevance of this finding is unknown.</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Delstrigo during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether doravirine is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of doravirine in milk (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Lamivudine has been identified in breast-fed newborns/infants of treated women. Based on more than 200&nbsp;mother/child pairs treated for HIV, serum concentrations of lamivudine in breast-fed infants of mothers treated for HIV are very low (&lt;&nbsp;4&nbsp;% of maternal serum concentrations) and progressively decrease to undetectable levels when breast-fed infants reach 24&nbsp;weeks of age. There are no data available on the safety of lamivudine when administered to babies less than three months old.</p><p><u>&nbsp;</u></p><p>Tenofovir is excreted in human milk. There is insufficient information on the effects of tenofovir in newborns/infants.</p><p><u>&nbsp;</u></p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No human data on the effect of Delstrigo on fertility are available. Animal studies do not indicate harmful effects of doravirine, lamivudine, or tenofovir disoproxil on fertility at exposure levels higher than the exposure in humans at the recommended clinical dose (see section&nbsp;5.3).</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Delstrigo has a minor influence on the ability to drive and use machines. Patients should be informed that fatigue, dizziness, and somnolence have been reported during treatment with Delstrigo (see section&nbsp;4.8). This should be considered when assessing a patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>In phase 3 clinical trials with doravirine plus 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs), the most frequently reported adverse reactions were nausea (4&nbsp;%) and headache (3&nbsp;%).</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u><u> </u></p><p>&nbsp;</p><p>The adverse reactions with doravirine plus 2 NRTIs from Phase 3 clinical trials (DRIVE FORWARD, DRIVE SHIFT and DRIVE AHEAD) are listed below by body system organ class and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000), or very rare (&lt;&nbsp;1/10&nbsp;000).</p><p>&nbsp;</p><p><strong>Table 2: Tabulated summary of adverse reactions associated with doravirine/lamivudine/tenofovir disoproxil</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>rash pustular</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic systems disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>neutropenia*, anaemia*, thrombocytopenia*</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>pure red cell aplasia*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>hypophosphataemia, hypokalaemia*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>hypomagnesaemia, lactic acidosis*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>abnormal dreams, insomnia<sup>1</sup>,</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>nightmare, depression<sup>2</sup>, anxiety<sup>3</sup>, irritability, confusional state, suicidal ideation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>aggression, hallucination, adjustment disorder, mood altered, somnambulism</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>headache, dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>disturbance in attention, memory impairment, paraesthesia, hypertonia, poor quality sleep</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>peripheral neuropathy (or paraesthesia)*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypertension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>cough*, nasal symptoms*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>dyspnoea, tonsillar hypertrophy</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>nausea, diarrhoea, abdominal pain<sup>4</sup>, vomiting, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>constipation, abdominal discomfort<sup>5</sup>, abdominal distension, dyspepsia, faeces soft<sup>6</sup>, gastrointestinal motility disorder<sup>7</sup>, pancreatitis*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>rectal tenesmus</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>hepatic steatosis*, hepatitis*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>alopecia*,<sup> </sup>rash<sup>8</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>dermatitis allergic, rosacea, angioedema*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>muscle disorders*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>myalgia, arthralgia, rhabdomyolysis*<sup>&dagger;</sup>, muscular weakness*<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>musculoskeletal pain, osteomalacia (manifested as bone pain and infrequently contributing to fractures)*, myopathy*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>increased creatinine*, proximal renal tubulopathy (including Fanconi syndrome)*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>acute kidney injury, renal disorder, calculus urinary, nephrolithiasis, acute renal failure*, renal failure*, acute tubular necrosis*, nephritis (including acute interstitial)*, nephrogenic diabetes insipidus*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>fatigue, fever*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>asthenia, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>chest pain, chills, pain, thirst</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>alanine aminotransferase increased<sup>9</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>aspartate aminotransferase increased, lipase increased, amylase increased, haemoglobin decreased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>blood creatine phosphokinase increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p>*This adverse reaction was not identified as an adverse reaction associated with doravirine from the Phase&nbsp;3 clinical studies (DRIVE-FORWARD, DRIVE-AHEAD, DRIVE-SHIFT), but is included in this table as an adverse reaction based on the Summary of Product Characteristics of 3TC and/or TDF. The highest frequency category reported in the 3TC or TDF Summary of Product Characteristics is used.</p><p><sup>&dagger;</sup>This adverse reaction may occur as a consequence of proximal renal tubulopathy. It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition.</p><p><sup>1</sup>insomnia includes: insomnia, initial insomnia and sleep disorder.</p><p><sup>2</sup>depression includes: depression, depressed mood, major depression, and persistent depressive disorder.</p><p><sup>3</sup>anxiety includes: anxiety and generalised anxiety disorder.</p><p><sup>4</sup>abdominal pain includes: abdominal pain, and abdominal pain upper.</p><p><sup>5</sup>abdominal discomfort includes: abdominal discomfort, and epigastric discomfort.</p><p><sup>6</sup>faeces soft includes: faeces soft and abnormal faeces.</p><p><sup>7</sup>gastrointestinal motility disorder includes: gastrointestinal motility disorder, and frequent bowel movements.</p><p><sup>8</sup>rash includes: rash, rash macular, rash erythematous, rash generalised, rash maculo-papular, rash papular, and urticarial.</p><p><sup>9</sup>alanine aminotransferase increased<sup> </sup>includes: alanine aminotransferase increased<sup> </sup>&nbsp;and<sup> </sup>hepatocellular injury.</p><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><u>Immune reactivation syndrome</u><u>&nbsp; </u></p><p>&nbsp;</p><p>In HIV‑infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Lactic acidosis</u><u> </u></p><p>&nbsp;</p><p>Cases of lactic acidosis have been reported with tenofovir disoproxil alone or in combination with other antiretrovirals. Patients with predisposing factors such as patients with decompensated liver disease, or patients receiving concomitant medicinal products known to induce lactic acidosis are at increased risk of experiencing severe lactic acidosis during tenofovir disoproxil treatment, including fatal outcomes.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety of doravirine/lamivudine/tenofovir disoproxil was evaluated in 45 HIV-1 infected virologically suppressed or treatment-na&iuml;ve paediatric patients 12 to less than 18&nbsp;years of age through Week&nbsp;48 in an open-label trial (IMPAACT&nbsp;2014 (Protocol&nbsp;027)). The safety profile in paediatric subjects was similar to that in adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Doravirine</u></p><p>&nbsp;</p><p>There is no information on potential acute symptoms and signs of overdose with doravirine.</p><p>&nbsp;</p><p><u>Lamivudine</u></p><p>&nbsp;</p><p>Because a negligible amount of lamivudine was removed via (4‑hour) haemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous haemodialysis would provide clinical benefit in a lamivudine overdose event.</p><p>&nbsp;</p><p><u>Tenofovir disoproxil</u></p><p>&nbsp;</p><p>Tenofovir disoproxil is efficiently removed by haemodialysis with an extraction coefficient of approximately 54&nbsp;%. Following a single 245&nbsp;mg dose of tenofovir disoproxil, a 4-hour haemodialysis session removed approximately 10&nbsp;% of the administered tenofovir dose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, ATC code: J05AR24</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV‑1 and inhibits HIV‑1 replication by non-competitive inhibition of HIV‑1 reverse transcriptase (RT). Doravirine does not inhibit the human cellular DNA polymerases &alpha;, &szlig;, and mitochondrial DNA polymerase &gamma;.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Lamivudine is a nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5&acute;‑ triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC‑TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em><em> </em></p><p>Tenofovir disoproxil is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV‑1 RT by competing with the natural substrate deoxyadenosine 5&acute;-triphosphate and, after incorporation into DNA, by DNA chain<em> </em>termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases &alpha;, &beta;, and<em> </em>mitochondrial DNA polymerase &gamma;.</p><p><u>&nbsp;</u></p><p><u>Antiviral activity in cell culture</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine exhibited an EC<sub>50 </sub>value of 12.0&plusmn;4.4 nM against wild-type laboratory strains of HIV‑1 when tested in the presence of 100&nbsp;% normal human serum using MT4-GFP reporter cells. Doravirine demonstrated antiviral activity against a broad panel of primary HIV‑1 isolates (A, A1, AE, AG, B, BF, C, D, G, H) with EC<sub>50</sub> values ranging from 1.2&nbsp;nM to 10.0&nbsp;nM. The antiviral activity of doravirine was not antagonistic when combined with lamivudine and tenofovir disoproxil.</p><p><u>&nbsp;</u></p><p><em>Lamivudine</em></p><p>The antiviral activity of lamivudine against HIV‑1 was assessed in a number of cell lines including monocytes and peripheral blood mononuclear cells (PBMCs) using standard susceptibility assays. EC<sub>50</sub> values were in the range of 0.003 to 15&nbsp;microM (1&nbsp;microM = 0.23&nbsp;micrograms per mL). The median EC<sub>50</sub> values of lamivudine were 60&nbsp;nM (range: 20 to 70&nbsp;nM), 35&nbsp;nM (range: 30 to 40&nbsp;nM), 30&nbsp;nM (range: 20 to 90&nbsp;nM), 20&nbsp;nM (range: 3 to 40&nbsp;nM), 30&nbsp;nM (range: 1 to 60&nbsp;nM), 30&nbsp;nM (range: 20&nbsp;to 70&nbsp;nM), 30&nbsp;nM (range: 3 to 70&nbsp;nM), and 30&nbsp;nM (range: 20 to 90&nbsp;nM) against HIV‑1 clades A‑G and group O viruses (n&nbsp;=&nbsp;3 except n&nbsp;=&nbsp;2 for clade B) respectively. Ribavirin (50&nbsp;microM) used in the treatment of chronic HCV infection decreased the anti-HIV‑1 activity of lamivudine by 3.5-fold in MT-4 cells.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em><em> </em></p><p>The antiviral activity of tenofovir against laboratory and clinical isolates of HIV‑1 was assessed in T&nbsp;lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes. The EC<sub>50</sub> values for tenofovir were in the range of 0.04‑8.5&nbsp;microM. Tenofovir displayed antiviral activity in cell culture against HIV‑1 clades A, B, C, D, E, F, G, and O (EC<sub>50</sub> values ranged from 0.5‑2.2&nbsp;microM).</p><p>&nbsp;</p><p><u>Resistance</u></p><p>&nbsp;</p><p><em>In cell culture</em></p><p><em>Doravirine</em></p><p>Doravirine-resistant strains were selected in cell culture starting from wild-type HIV‑1 of different origins and subtypes, as well as NNRTI-resistant HIV‑1. Observed emergent amino acid substitutions in RT included: V106A, V106M, V106I, V108I, F227L, F227C, F227I, F227V, H221Y, M230I, L234I, P236L, and Y318F. The V106A, V106M, V108I, H221Y, F227C, M230I, P236L, and Y318F substitutions conferred 3.4-fold to 70-fold reductions in susceptibility to doravirine. Y318F in combination with V106A, V106M, V108I, and F227C conferred greater decreases in susceptibility to doravirine than Y318F alone, which conferred a 10-fold reduction in susceptibility to doravirine. Common NNRTI-resistant mutations (K103N, Y181C) were not selected in the <em>in vitro</em> study. V106A (yielding a fold change of around 19) appeared as an initial substitution in subtype&nbsp;B virus, and V106A or M in subtype A and C virus. Subsequently F227(L/C/V) or L234I emerged in addition to V106 substitutions (double mutants yielding a fold change of &gt;&nbsp;100).</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Lamivudine-resistant variants of HIV‑1 have been selected in cell culture and in subjects treated with lamivudine. Genotypic analysis showed that the resistance was due to a specific amino acid substitution in the HIV‑1 RT at codon 184 changing the methionine to either isoleucine or valine (M184V/I).</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em><em> </em></p><p>HIV‑1 isolates selected by tenofovir expressed a K65R substitution in HIV‑1 RT and showed a 2‑4&nbsp;fold reduction in susceptibility to tenofovir. In addition, a K70E substitution in HIV‑1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, lamivudine, and tenofovir.</p><p>&nbsp;</p><p><em>In clinical trials</em></p><p><em>Treatment</em><em>-</em><em>na&iuml;ve adult subjects</em></p><p><em>Doravirine</em></p><p>The Phase 3 studies, DRIVE-FORWARD and DRIVE-AHEAD, included previously untreated patients (n&nbsp;=&nbsp;747) where the following NNRTI substitutions were part of exclusion criteria: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V.</p><p>&nbsp;</p><p>The following de novo resistance was seen in the resistance analysis subset (subjects with HIV‑1 RNA greater than 400&nbsp;copies per mL at virologic failure or at early study discontinuation and having resistance data).</p><p><em>&nbsp;</em></p><p><strong>Table 3: Resistance development up to </strong><strong>Week</strong><strong> 96 in protocol defined virologic failure population + early discontinuation population</strong><br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p>DRIVE-FORWARD</p></td><td colspan="2" style="vertical-align:top"><p>DRIVE-AHEAD</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>DOR + NRTIs*</p><p>(383)</p></td><td style="vertical-align:top"><p>DRV+r + NRTIs*</p><p>(383)</p></td><td style="vertical-align:top"><p>DOR/TDF/3TC<br />(364)</p></td><td style="vertical-align:top"><p>EFV/TDF/FTC<br />(364)</p></td></tr><tr><td style="vertical-align:top"><p>Successful genotype, n</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>Genotypic resistance to</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>DOR or control (DRV or EFV)</p></td><td style="vertical-align:top"><p>2 (DOR)</p></td><td style="vertical-align:top"><p>0 (DRV)</p></td><td style="vertical-align:top"><p>8 (DOR)</p></td><td style="vertical-align:top"><p>14 (EFV)</p></td></tr><tr><td style="vertical-align:top"><p>NRTI backbone</p><p>M184I/V only</p><p>K65R only</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; K65R + M184I/V</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2<sup>**</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>6</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p></td><td style="vertical-align:top"><p>5</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*NRTI in DOR arm: FTC/TDF (333) or ABC/3TC (50); NRTI in DRV+r arm: FTC/TDF (335) or ABC/3TC (48)</p><p>**Subjects received FTC/TDF</p><p>ABC=abacavir; FTC=emtricitabine; DRV=darunavir; r=ritonavir</p></td></tr></tbody></table><p>&nbsp;</p><p>Emergent doravirine associated resistance substitutions in RT included one or more of the following: A98G, V106I, V106A, V106M/T, Y188L, H221Y, P225H, F227C, F227C/R, and Y318Y/F.</p><p><em>&nbsp;</em></p><p><em>Virologically suppressed adult subjects</em></p><p>The DRIVE-SHIFT study included virologically suppressed patients (N=670) with no history of treatment failure (see section, Clinical experience). A documented absence of genotypic resistance (prior to starting first therapy) to doravirine, lamivudine, and tenofovir was part of the inclusion criteria for patients who switched from a PI- or INI-based regimen. &nbsp;Exclusionary NNRTI substitutions were those listed above (DRIVE-FORWARD and DRIVE-AHEAD), with the exception of substitutions RT K103N, G190A and Y181C (accepted in DRIVE-SHIFT). &nbsp;Documentation of pre‑treatment resistance genotyping was not required for patients who switched from a NNRTI-based regimen.</p><p><em>&nbsp;</em></p><p>In the DRIVE-SHIFT clinical trial, no subjects developed genotypic or phenotypic resistance to DOR, 3TC, or TDF during the initial 48 weeks (immediate switch, N=447) or 24 weeks (delayed switch, N=209) of treatment with Delstrigo. &nbsp;One subject developed RT M184M/I mutation and phenotypic resistance to 3TC and FTC during treatment with their baseline regimen. &nbsp;None of the 24&nbsp;subjects (11 in the immediate switch group, 13 in the delayed switch group) with baseline NNRTI mutations (RT K103N, G190A, or Y181C) experienced virologic failure through Week&nbsp;48, or at time of discontinuation.</p><p>&nbsp;</p><p><em>Paediatric subjects</em></p><p>In the IMPAACT&nbsp;2014 (Protocol 027) clinical trial, no subject who was virologically suppressed at baseline met the criteria for resistance analysis. One treatment-na&iuml;ve subject who met the protocol‑defined virologic failure criteria (defined as 2&nbsp;consecutive plasma HIV-1 RNA test results &ge;200&nbsp;copies/mL) at or after Week&nbsp;24 was evaluated for the development of resistance; no emergence of genotypic or phenotypic resistance to doravirine, lamivudine or tenofovir was detected.</p><p>&nbsp;</p><p><u>Cross-resistance</u></p><p>&nbsp;</p><p>No significant cross-resistance has been demonstrated between doravirine-resistant HIV‑1 variants and lamivudine/emtricitabine or tenofovir or between lamivudine- or tenofovir-resistant variants and doravirine.</p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine has been evaluated in a limited number of patients with NNRTI resistance (K103N n&nbsp;=&nbsp;7, G190A n&nbsp;=&nbsp;1); all patients were suppressed to &lt;&nbsp;40 copies/mL at Week&nbsp;48. A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established.</p><p>&nbsp;</p><p>Laboratory strains of HIV‑1 harbouring the common NNRTI-associated mutations K103N, Y181C, or K103N/Y181C substitutions in RT exhibit less than a 3-fold decrease in susceptibility to doravirine compared to wild-type virus when evaluated in the presence of 100&nbsp;% normal human serum. In <em>in</em><em>&nbsp;</em><em>vitro</em> studies, doravirine was able to suppress the following NNRTI-associated substitutions; K103N, Y181C, and G190A under clinically relevant concentrations.</p><p>&nbsp;</p><p>A panel of 96 diverse clinical isolates containing NNRTI-associated mutations was evaluated for susceptibility to doravirine in the presence of 10&nbsp;% foetal bovine serum. Clinical isolates containing the Y188L substitution or V106 substitutions in combination with A98G, H221Y, P225H, F227C or Y318F showed a greater than 100-fold reduced susceptibility to doravirine. Other substitutions yielded a fold change of 5-10 (G190S (5.7); K103N/P225H (7.9), V108I/Y181C (6.9), Y181V (5.1)). The clinical relevance of a 5-10 fold change reduction in susceptibility is unknown.</p><p>&nbsp;</p><p>Treatment emergent doravirine resistance associated substitutions may confer cross-resistance to efavirenz, rilpivirine, nevirapine, and etravirine. Of the 8 subjects who developed high level doravirine resistance in the pivotal studies, 6 had phenotypic resistance to EFV and nevirapine, 3 to rilpivirine, and 3 had partial resistance to etravirine based on the Monogram Phenosense assay.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Cross-resistance has been observed among NRTIs. The M184I/V lamivudine resistance substitution confers resistance to emtricitabine. Lamivudine-resistant HIV‑1 mutants were also cross resistant to didanosine (ddI). In some subjects treated with zidovudine plus didanosine, isolates resistant to multiple RT inhibitors, including lamivudine, have emerged.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em><em> </em></p><p>Cross-resistance has been observed among NRTIs. The K65R substitution in HIV‑1 RT selected by tenofovir is also selected in some HIV‑1 infected patients treated with abacavir or didanosine. HIV‑1 isolates with the K65R substitution also showed reduced susceptibility to emtricitabine and lamivudine. Therefore, cross-resistance among these NRTIs may occur in patients whose virus harbours the K65R substitution. The K70E substitution selected clinically by tenofovir disoproxil results in reduced susceptibility to abacavir, didanosine, emtricitabine, lamivudine, and tenofovir. HIV‑1 isolates from patients (n&nbsp;=&nbsp;20) whose HIV‑1 expressed a mean of 3 zidovudine&shy; associated RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility to tenofovir. Subjects whose virus expressed an L74V RT substitution without zidovudine resistance-associated substitutions (n&nbsp;=&nbsp;8) had reduced response to tenofovir disoproxil. Limited data are available for patients whose virus expressed a Y115F substitution (n&nbsp;=&nbsp;3), Q151M substitution (n&nbsp;=&nbsp;2), or T69 insertion (n&nbsp;=&nbsp;4) in HIV‑1 RT, all of whom had a reduced response in clinical trials.</p><p><u>&nbsp;</u></p><p><u>Clinical experience</u></p><p><u>&nbsp;</u></p><p><em>Treatment-na&iuml;ve adult subjects</em></p><p>The efficacy of doravirine is based on the analyses of 96-week data from two randomised, multicentre, double-blind, active controlled Phase 3 trials, (DRIVE-FORWARD and DRIVE‑AHEAD) in antiretroviral treatment-na&iuml;ve, HIV‑1 infected subjects (n = 1494). Refer to Resistance section for NNRTI substitutions that were part of exclusion criteria.</p><p>&nbsp;</p><p>In DRIVE-FORWARD, 766 subjects were randomised and received at least 1 dose of either doravirine 100&nbsp;mg or darunavir + ritonavir 800+100&nbsp;mg once daily, each in combination with emtricitabine/tenofovir disoproxil (FTC/TDF) or abacavir/lamivudine (ABC/3TC) selected by the investigator. At baseline, the median age of subjects was 33 years (range 18 to 69 years), 86&nbsp;% had CD4<sup>+</sup> T cell count greater than 200&nbsp;cells per mm<sup>3</sup>, 84&nbsp;% were male, 27&nbsp;% were non-white, 4&nbsp;% had hepatitis B and/or C virus co-infection, 10&nbsp;% had a history of AIDS, 20&nbsp;% had HIV‑1 RNA greater than 100&nbsp;000&nbsp;copies per mL, 13&nbsp;% received ABC/3TC and 87&nbsp;% received FTC/TDF; these characteristics were similar between treatment groups.</p><p>&nbsp;</p><p>In DRIVE-AHEAD, 728 subjects were randomised and received at least 1 dose of either doravirine/lamivudine/tenofovir disoproxil 100/300/245&nbsp;mg (DOR/3TC/TDF) or efavirenz/emtricitabine/tenofovir disoproxil (EFV/FTC/TDF) once daily. At baseline, the median age of subjects was 31&nbsp;years (range 18‑70&nbsp;years), 85&nbsp;% were male, 52&nbsp;% were non-white, 3&nbsp;% had hepatitis B or C co-infection, 14&nbsp;% had a history of AIDS, 21&nbsp;% had HIV‑1 RNA &gt;&nbsp;100&nbsp;000 copies per mL, and 12&nbsp;% had CD4<sup>+</sup> T cell count &lt;&nbsp;200 cells per mm<sup>3</sup>; these characteristics were similar between treatment groups.</p><p>&nbsp;</p><p>Week&nbsp;48 and&nbsp;96 outcomes for DRIVE-FORWARD and DRIVE-AHEAD are provided in Table&nbsp;4. The doravirine-based regimens demonstrated consistent efficacy across demographic and baseline prognostic factors.</p><p><u>&nbsp;</u></p><p><strong>Table 4: </strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ansi-language:EN-US'><span style='mso-element:field-begin;mso-field-lock:
yes'></span><span style='mso-spacerun:yes'> </span>INCLUDETEXT
&quot;\\\\bardsar-prod\\mk1439a-hiv\\prot021-wk48-sdtm313\\outtable\\ef0vlout0w48.rtf&quot;
\c MSRTF<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>Efficacy response (&lt;&nbsp;40 copies/mL, Snapshot approach) in the pivotal studies</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ansi-language:EN-US'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>DRIVE-FORWARD</strong></p></td><td colspan="2"><p><strong>DRIVE-AHEAD</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DOR + 2 NRTIs (383)</strong></p></td><td style="vertical-align:top"><p><strong>DRV+r</strong><strong> + 2 NRTIs (383)</strong></p></td><td style="vertical-align:top"><p><strong>DOR/3TC/TDF</strong></p><p><strong>(364)</strong></p></td><td style="vertical-align:top"><p><strong>EFV/FTC/TDF</strong></p><p><strong>(364)</strong></p></td></tr><tr><td><p>Week&nbsp;48</p></td><td><p>83&nbsp;%</p></td><td><p>79&nbsp;%</p></td><td><p>84&nbsp;%</p></td><td><p>80&nbsp;%</p></td></tr><tr><td><p>Difference (95&nbsp;% CI)</p></td><td colspan="2"><p>4.2&nbsp;% (-1.4%, 9.7&nbsp;%)</p></td><td colspan="2"><p>4.1&nbsp;% (-1.5&nbsp;%, 9.7&nbsp;%)</p></td></tr><tr><td><p>Week&nbsp;96*</p></td><td><p>72&nbsp;% (N=379)</p></td><td><p>64&nbsp;% (N=376)</p></td><td><p>76&nbsp;% (N=364)</p></td><td><p>73&nbsp;% (N=364)</p></td></tr><tr><td><p>Difference (95&nbsp;% CI)</p></td><td colspan="2"><p>7.6&nbsp;% (1.0&nbsp;%, 14.2&nbsp;%)</p></td><td colspan="2"><p>3.3&nbsp;% (-3.1&nbsp;%, 9.6&nbsp;%)</p></td></tr><tr><td colspan="5"><p><strong>Week</strong><strong>&nbsp;</strong><strong>48 outcome (&lt;</strong><strong>&nbsp;</strong><strong>40 copies/mL) by baseline factors</strong></p></td></tr><tr><td colspan="5"><p>HIV‑1 RNA copies/mL</p></td></tr><tr><td><p>&le; 100&nbsp;000</p></td><td><p>256/285 (90&nbsp;%)</p></td><td><p>248/282 (88&nbsp;%)</p></td><td><p>251/277 (91&nbsp;%)</p></td><td><p>234/258 (91&nbsp;%)</p></td></tr><tr><td><p>&gt;&nbsp;100&nbsp;000&nbsp;</p></td><td><p>63/79 (80&nbsp;%)</p></td><td><p>54/72 (75&nbsp;%)</p></td><td><p>54/69 (78 %)</p></td><td><p>56/73 (77&nbsp;%)</p></td></tr><tr><td colspan="5"><p>CD4 count, cells/&micro;L</p></td></tr><tr><td><p>&le;&nbsp;200</p></td><td><p>34/41 (83&nbsp;%)</p></td><td><p>43/61 (70&nbsp;%)</p></td><td><p>27/42 (64&nbsp;%)</p></td><td><p>35/43 (81&nbsp;%)</p></td></tr><tr><td><p>&gt;&nbsp;200</p></td><td><p>285/323 (88&nbsp;%)</p></td><td><p>260/294 (88&nbsp;%)</p></td><td><p>278/304 (91&nbsp;%)</p></td><td><p>255/288 (89&nbsp;%)</p></td></tr><tr><td colspan="5"><p>NRTI background therapy&nbsp;&nbsp;</p></td></tr><tr><td><p>&nbsp; TDF/FTC</p></td><td><p>276/316 (87&nbsp;%)</p></td><td><p>267/312 (86&nbsp;%)</p></td><td colspan="2"><p>NA</p></td></tr><tr><td><p>ABC/3TC</p></td><td><p>43/48 (90&nbsp;%)</p></td><td><p>36/43 (84&nbsp;%)</p></td><td colspan="2"><p>NA</p></td></tr><tr><td colspan="5"><p>Viral subtype&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>B</p></td><td><p>222/254 (87&nbsp;%)</p></td><td><p>219/255 (86&nbsp;%)</p></td><td><p>194/222 (87&nbsp;%)</p></td><td><p>199/226 (88&nbsp;%)</p></td></tr><tr><td><p>non-B</p></td><td><p>97/110 (88&nbsp;%)</p></td><td><p>84/100 (84&nbsp;%)</p></td><td><p>109/122 (89&nbsp;%)</p></td><td><p>91/105 (87&nbsp;%)</p></td></tr><tr><td colspan="5"><p><strong>Mean CD4 change from baseline</strong></p></td></tr><tr><td><p>Week&nbsp;48</p></td><td><p>193</p></td><td><p>186</p></td><td><p>198</p></td><td><p>188</p></td></tr><tr><td><p>Week&nbsp;96</p></td><td><p>224</p></td><td><p>207</p></td><td><p>238</p></td><td><p>223</p></td></tr></tbody></table><p>*For Week&nbsp;96, certain subjects with missing HIV‑1 RNA were excluded from the analysis.</p><p>&nbsp;</p><p><em>Virologically suppressed adult subjects</em></p><p>The efficacy of switching from a baseline regimen consisting of two nucleoside reverse transcriptase inhibitors in combination with a ritonavir- or cobicistat-boosted PI, or cobicistat-boosted elvitegravir, or an NNRTI to Delstrigo was evaluated in a randomised, open-label trial (DRIVE-SHIFT), in virologically suppressed HIV-1 infected adults. Subjects must have been virologically suppressed (HIV-1 RNA &lt;&nbsp;40 copies/mL) on their baseline regimen for at least 6&nbsp;months prior to trial entry, with no history of virologic failure, and a documented absence of RT substitutions conferring resistance to doravirine, lamivudine and tenofovir (see section, Resistance). Subjects were randomised to either switch to Delstrigo at baseline [N= 447, Immediate Switch Group (ISG)], or stay on their baseline regimen until Week&nbsp;24, at which point they switched to Delstrigo [N= 223, Delayed Switch Group (DSG)]. At baseline, the median age of subjects was 43&nbsp;years, 16&nbsp;% were female, and 24&nbsp;% were non-white.</p><p>&nbsp;</p><p>In the DRIVE-SHIFT trial, an immediate switch to Delstrigo was demonstrated to be non-inferior at Week&nbsp;48 compared to continuation of the baseline regimen at Week&nbsp;24 as assessed by the proportion of subjects with HIV-1 RNA &lt;&nbsp;40 copies/mL. Treatment results are shown in Table&nbsp;5. Consistent results were seen for the comparison at study Week&nbsp;24 in each treatment group.</p><p>&nbsp;</p><p>Table 5: Efficacy response (Snapshot approach) in the DRIVE-SHIFT study</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Outcome</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Delstrigo</strong></p><p><strong>Once Daily ISG </strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Baseline Regimen DSG</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;48 </strong></p><p><strong>N=447</strong></p></td><td style="vertical-align:top"><p><strong>Week&nbsp;24 </strong></p><p><strong>N=223</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HIV-1 RNA &lt;&nbsp;40 copies/mL</strong></p></td><td style="vertical-align:top"><p>90&nbsp;%</p></td><td style="vertical-align:top"><p>93&nbsp;%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; ISG-DSG, Difference (95&nbsp;% CI)*</p></td><td colspan="2" style="vertical-align:top"><p>-3.6&nbsp;% (-8.0&nbsp;%, 0.9&nbsp;%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proportion (%) of Subjects With HIV-1 RNA &lt;&nbsp;40 copies/mL by Baseline Regimen Received</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir- or Cobicistat- boosted PI</p></td><td style="vertical-align:top"><p>280/316 (89&nbsp;%)</p></td><td style="vertical-align:top"><p>145/156 (93&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Cobicistat-boosted elvitegravir&nbsp;</p></td><td style="vertical-align:top"><p>23/25 (92&nbsp;%)</p></td><td style="vertical-align:top"><p>11/12 (92&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>NNRTI&nbsp;</p></td><td style="vertical-align:top"><p>98/106 (92&nbsp;%)</p></td><td style="vertical-align:top"><p>52/55 (95&nbsp;%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proportion (%) of Subjects With HIV-1 RNA &lt;</strong>&nbsp;<strong>40 copies/mL by Baseline CD4<sup>+</sup> T cell Count (cells/mm<sup>3</sup>)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &lt;&nbsp;200 cells/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>10/13 (77&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3/4 (75&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;200 cells/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>384/426 (90&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>202/216 (94&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>HIV-1 RNA &ge;</strong>&nbsp;<strong>40 copies/mL</strong><strong><sup>&dagger;</sup></strong></p></td><td style="vertical-align:top"><p>3&nbsp;%</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>No Virologic Data Within the Time Window&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>8&nbsp;%</p></td><td style="vertical-align:top"><p>3&nbsp;%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Discontinued study due to AE or Death<sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Discontinued study for Other Reasons<sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4&nbsp;%</p></td><td style="vertical-align:top"><p>&nbsp; 3&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; On study but missing data in window&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*The 95&nbsp;% CI for the treatment difference was calculated using stratum-adjusted Mantel-Haenszel method.</p><p><sup>&dagger;</sup>Includes subjects who discontinued study treatment or study before Week&nbsp;48 for ISG or before Week&nbsp;24 for DSG for lack or loss of efficacy and subjects with HIV-1 RNA &ge;&nbsp;40 copies/mL in the Week&nbsp;48 window for ISG and in the Week&nbsp;24 window for DSG.</p><p><sup>&Dagger;</sup>Includes subjects who discontinued because of adverse event (AE) or death if this resulted in no virologic data on treatment during the specified window.</p><p><sup>&sect;</sup>Other reasons include: lost to follow-up, non-compliance with study treatment, physician decision, protocol deviation, withdrawal by subject.</p><p>Baseline regimen = ritonavir or cobicistat-boosted PI (specifically atazanavir, darunavir, or lopinavir), or</p><p>cobicistat-boosted elvitegravir, or NNRTI (specifically efavirenz, nevirapine, or rilpivirine), each</p><p>administered with two NRTIs.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Discontinuation due to adverse events</u></p><p>&nbsp;</p><p>In DRIVE-AHEAD, a lower proportion of subjects who discontinued due to an adverse event by Week&nbsp;48 was seen for the Delstrigo group (3.0&nbsp;%) compared with the EFV/FTC/TDF group (6.6&nbsp;%).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The efficacy of DOR/3TC/TDF was evaluated in an open-label, single-arm trial in HIV-1 infected paediatric patients 12 to less than 18&nbsp;years of age (IMPAACT 2014 (Protocol 027)).</p><p>&nbsp;</p><p>At baseline, the median age of subjects was 15&nbsp;years (range: 12 to 17), 58% were female, 78% were Asian and 22% were Black, and the median CD4+ T-cell count was 713&nbsp;cells per mm<sup>3</sup> (range:&nbsp;84 to 1,397). After switching to DOR/3TC/TDF, 95% (41/43) of virologically-suppressed subjects remained suppressed (HIV-1 RNA &lt;&nbsp;50&nbsp;copies/mL) at Week&nbsp;24 and 93% (40/43) remained suppressed (HIV-1 RNA &lt; 50 copies/mL) at Week 48.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Delstrigo in one or more subsets of the paediatric population in treatment of human immunodeficiency virus-1 (HIV‑1) infection. See&nbsp;section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single-dose administration of one doravirine/lamivudine/tenofovir disoproxil tablet to healthy subjects (N&nbsp;=&nbsp;24) under fasted conditions provided comparable exposures of doravirine, lamivudine, and tenofovir to administration of doravirine tablets (100&nbsp;mg) plus lamivudine tablets (300&nbsp;mg) plus tenofovir disoproxil tablets (245&nbsp;mg). The administration of a single Delstrigo tablet with a high-fat meal to healthy subjects resulted in a 26&nbsp;% increase in doravirine C<sub>24</sub>, while AUC and C<sub>max</sub> were not significantly affected. Lamivudine C<sub>max</sub> decreased by 19&nbsp;% with a high fat meal, while AUC was not significantly affected. Tenofovir C<sub>max</sub> decreased by 12&nbsp;% and AUC increased by 27&nbsp;% with a high fat meal. These differences in pharmacokinetics are not clinically relevant.</p><p>&nbsp;</p><p><em>Doravirine</em></p><p>The pharmacokinetics of doravirine were studied in healthy subjects and HIV‑1-infected subjects. Doravirine pharmacokinetics are similar in healthy subjects and HIV‑1-infected subjects. Steady state was generally achieved by Day&nbsp;2 of once daily dosing, with accumulation ratios of 1.2 to 1.4 for AUC<sub>0-24</sub>, C<sub>max</sub>, and C<sub>24</sub>. Doravirine steady state pharmacokinetics following administration of 100&nbsp;mg once daily to HIV‑1 infected subjects, based on a population pharmacokinetics analysis are provided below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Parameter</p><p>GM (&nbsp;%CV)</p></td><td><p>AUC<sub>0-24</sub></p><p>&micro;g&bull;h/mL</p></td><td><p>C<sub>max</sub></p><p>&micro;g/mL</p></td><td><p>C<sub>24</sub></p><p>&micro;g/mL</p></td></tr><tr><td><p>Doravirine</p><p>100&nbsp;mg</p><p>once daily</p></td><td><p>16.1 (29)</p></td><td><p>0.962 (19)</p></td><td><p>0.396 (63)</p></td></tr><tr><td colspan="4"><p>GM: Geometric mean, &nbsp;%CV: Geometric coefficient of variation</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following oral dosing, peak plasma concentrations are achieved 2&nbsp;hours after dosing. Doravirine has an estimated absolute bioavailability of approximately 64&nbsp;% for the 100&nbsp;mg tablet.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>Based on administration of an intravenous microdose, the volume of distribution of doravirine is 60.5&nbsp;L. Doravirine is approximately 76&nbsp;% bound to plasma proteins.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Based on <em>in vitro</em> data, doravirine is primarily metabolised by CYP3A.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p><em>Doravirine</em><br />Doravirine has a terminal half-life (t<sub>1/2</sub>) of approximately 15&nbsp;hours. Doravirine is primarily eliminated via oxidative metabolism mediated by CYP3A4. Biliary excretion of unchanged medicinal product may contribute to the elimination of doravirine, but this elimination route is not expected to be significant. Excretion of unchanged medicinal product via urinary excretion is minor.</p><p>&nbsp;</p><p><em>Lamivudine</em><em> </em><br />Following oral administration, lamivudine is rapidly absorbed and extensively distributed. After multiple-dose oral administration of lamivudine 300&nbsp;mg once daily for 7&nbsp;days to 60&nbsp;healthy subjects, steady-state C<sub>max</sub> (C<sub>max,ss</sub>) was 2.04 &plusmn; 0.54&nbsp;microgram per mL (mean &plusmn; SD) and the 24-hour steady-state AUC (AUC<sub>24,ss</sub>) was 8.87 &plusmn; 1.83&nbsp;mcg&bull;hour per mL. Binding to plasma protein is low. Approximately 71&nbsp;% of an intravenous dose of lamivudine is recovered as unchanged medicinal product in the urine. Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite is the trans-sulphoxide metabolite (approximately 5&nbsp;% of an oral dose after 12&nbsp;hours). In most single-dose trials in HIV‑1 infected subjects, or healthy subjects with serum sampling for 24&nbsp;hours after dosing, the observed mean elimination half-life (t<sub>&frac12;</sub>) ranged from 5 to 7&nbsp;hours. In HIV‑1&ndash;infected subjects, total clearance was 398.5 &plusmn; 69.1&nbsp;mL/min (mean &plusmn; SD).</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Following oral administration of a single 245&nbsp;mg dose of tenofovir disoproxil to HIV‑1-infected subjects in the fasted state, C<sub>max</sub> was achieved in one hour. C<sub>max</sub> and AUC values were 0.30&nbsp; &plusmn; &nbsp;0.09&nbsp;micrograms per mL and 2.29 &plusmn; 0.69&nbsp;&micro;g&bull;hr per mL, respectively. The oral bioavailability of tenofovir from tenofovir disoproxil in fasted subjects is approximately 25&nbsp;%. Less than 0.7&nbsp;% of tenofovir binds to human plasma proteins <em>in vitro</em> over the range of 0.01 to 25&nbsp;micrograms per mL. Approximately 70-80&nbsp;% of the intravenous dose of tenofovir is recovered as unchanged medicinal product in the urine within 72&nbsp;hours of dosing. Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion with a renal clearance in adults with CrCl greater than 80&nbsp;mL per minute of 243.5 &plusmn; 33.3&nbsp;mL per minute (mean &plusmn; SD). Following oral administration, the terminal half-life of tenofovir is approximately 12 to 18&nbsp;hours. <em>In vitro </em>studies have determined that neither tenofovir disoproxil nor tenofovir are substrates for the CYP450 enzymes.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Renal excretion of doravirine is minor. In a study comparing 8&nbsp;subjects with severe renal impairment to 8&nbsp;subjects without renal impairment, the single dose exposure of doravirine was 31&nbsp;% higher in subjects with severe renal impairment. In a population pharmacokinetic analysis, which included subjects with CrCl between 17 and 317&nbsp;mL/min, renal function did not have a clinically relevant effect on doravirine pharmacokinetics. No dose adjustment is required in patients with mild, moderate or severe renal impairment. Doravirine has not been studied in patients with end-stage renal disease or in patients undergoing dialysis (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal</p><p>dysfunction due to decreased clearance. Based on the lamivudine data, Delstrigo is not recommended for patients with CrCl of &lt;&nbsp;50&nbsp;mL/min.</p><p><u>&nbsp;</u></p><p><em>Tenofovir disoproxil</em></p><p>Pharmacokinetic parameters of tenofovir were determined following administration of a single dose of tenofovir disoproxil 245&nbsp;mg to 40&nbsp;non‑HIV infected adult subjects with varying degrees of renal impairment defined according to baseline CrCl (normal renal function when CrCl &gt;&nbsp;80&nbsp;mL/min; mild with CrCl = 50-79&nbsp;mL/min; moderate with CrCl = 30-49&nbsp;mL/min and severe with CrCl = 10‑29&nbsp;mL/min). Compared with subjects with normal renal function, the mean (%&nbsp;CV) tenofovir exposure increased from 2,185 (12&nbsp;%) ng&bull;h/mL in subjects with CrCl &gt;&nbsp;80&nbsp;mL/min to respectively 3,064 (30&nbsp;%) ng&bull;h/mL, 6,009 (42&nbsp;%) ng&bull;h/mL and 15,985 (45&nbsp;%) ng&bull;h/mL in subjects with mild, moderate, and severe renal impairment.</p><p>&nbsp;</p><p>The pharmacokinetics of tenofovir in non-haemodialysis adult subjects with CrCl &lt;&nbsp;10&nbsp;mL/min and in subjects with end-stage renal disease managed by peritoneal or other forms of dialysis have not been studied.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine is primarily metabolised and eliminated by the liver. There was no clinically relevant difference in the pharmacokinetics of doravirine in a study comparing 8&nbsp;subjects with moderate hepatic impairment (classified as Child-Pugh score B primarily due to increased encephalopathy and ascites scores) to 8&nbsp;subjects without hepatic impairment. No dose adjustment is required in patients with mild or moderate hepatic impairment. Doravirine has not been studied in subjects with severe hepatic impairment (Child-Pugh score C) (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Lamivudine</em><br />The pharmacokinetic properties of lamivudine have been determined in subjects with moderate to severe hepatic impairment. Pharmacokinetic parameters were not altered by diminishing hepatic function. Safety and efficacy of lamivudine have not been established in the presence of decompensated liver disease.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em><br />The pharmacokinetics of tenofovir following a 245&nbsp;mg dose of tenofovir disoproxil have been studied in healthy subjects with moderate to severe hepatic impairment. No clinically relevant differences in tenofovir pharmacokinetics were observed between subjects with hepatic impairment and healthy subjects.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Mean doravirine exposures were similar in 54&nbsp;paediatric patients aged 12 to less than 18&nbsp;years and weighing at least 35&nbsp;kg who received doravirine or doravirine/lamivudine/tenofovir disoproxil IMPAACT&nbsp;2014 (Protocol&nbsp;027) relative to adults following administration of doravirine or doravirine/lamivudine/tenofovir disoproxil. Exposures of lamivudine and tenofovir in paediatric subjects following the administration of doravirine/lamivudine/tenofovir disoproxil were similar to those in adults following administration of lamivudine and tenofovir disoproxil (Table&nbsp;6).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 6: Steady state pharmacokinetics for doravirine, lamivudine, and tenofovir following administration of doravirine or doravirine/lamivudine/tenofovir disoproxil in HIV infected paediatric patients aged 12 to less than 18&nbsp;years and weighing at least 35&nbsp;kg</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter*</strong></p></td><td style="vertical-align:top"><p><strong>Doravirine</strong><sup>&dagger;</sup></p></td><td style="vertical-align:top"><p><strong>Lamivudine</strong><sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p><strong>Tenofovir</strong><sup>&Dagger;</sup></p></td></tr><tr><td><p>AUC<sub>0-24</sub></p><p>(&micro;g&bull;h/mL)</p></td><td><p>16.4 (24)</p></td><td><p>11.3 (28)</p></td><td><p>2.55 (14)</p></td></tr><tr><td><p>C<sub>max</sub></p><p>(&micro;g/mL)</p></td><td style="vertical-align:top"><p>1.03 (16)</p></td><td style="vertical-align:top"><p>2.1 (24)</p></td><td style="vertical-align:top"><p>0.293 (37)</p></td></tr><tr><td><p>C<sub>24</sub></p><p>(&micro;g/mL)</p></td><td style="vertical-align:top"><p>0.379 (42)</p></td><td style="vertical-align:top"><p>0.0663 (55)</p></td><td style="vertical-align:top"><p>0.0502 (9)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*Presented as geometric mean (%CV: geometric coefficient of variation)</p><p><sup>&dagger;</sup>From population PK analysis (n=54)</p><p><sup>&Dagger;</sup>From intensive PK analysis (n=10)</p><p>Abbreviations: AUC=area under the time concentration curve; C<sub>max</sub>=maximum concentration; C<sub>24</sub>=concentration at 24&nbsp;hours</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p>&nbsp;</p><p>Although a limited number of subjects aged 65&nbsp;years and over has been included (n&nbsp;=&nbsp;36), no clinically relevant differences in the pharmacokinetics of doravirine have been identified in subjects at least 65&nbsp;years of age compared to subjects less than 65&nbsp;years of age in a Phase 1 trial or in a population pharmacokinetic analysis. The pharmacokinetics of lamivudine and tenofovir have not been studied in subjects older than 65&nbsp;years. No dose adjustment is required.</p><p><u>&nbsp;</u></p><p><u>Gender</u></p><p>&nbsp;</p><p>No clinically relevant pharmacokinetic differences have been identified between men and women for doravirine, lamivudine, and tenofovir.</p><p>&nbsp;</p><p><u>Race</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>No clinically relevant racial differences in the pharmacokinetics of doravirine have been identified based on a population pharmacokinetic analysis of doravirine in healthy and HIV‑1-infected subjects.</p><p><u>&nbsp;</u></p><p><em>Lamivudine</em></p><p>There are no significant or clinically relevant racial differences in pharmacokinetics of lamivudine.</p><p><u>&nbsp;</u></p><p><em>Tenofovir disoproxil</em></p><p>There were insufficient numbers from racial and ethnic groups other than Caucasian to adequately determine potential pharmacokinetic differences among these populations following the administration of tenofovir disoproxil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reproductive toxicity</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Reproduction studies with orally administered doravirine have been performed in rats and rabbits at exposures approximately 9&nbsp;times (rats) and 8&nbsp;times (rabbits) the exposure in humans at the recommended human dose (RHD) with no effects on embryo-foetal (rats and rabbits) or pre/postnatal (rats) development. Studies in pregnant rats and rabbits showed that doravirine is transferred to the foetus through the placenta, with foetal plasma concentrations of up to 40&nbsp;% (rabbits) and 52&nbsp;% (rats) that of maternal concentrations observed on gestation Day&nbsp;20.</p><p>&nbsp;</p><p>Doravirine was excreted into the milk of lactating rats following oral administration, with milk concentrations approximately 1.5&nbsp;times that of maternal plasma concentrations.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. A similar effect was not seen in rats even at very high systemic exposure.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. However, tenofovir disoproxil reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Long-term oral carcinogenicity studies of doravirine in mice and rats showed no evidence of carcinogenic potential at estimated exposures up to 6&nbsp;times (mice) and 7&nbsp;times (rats) the human exposures at the RHD.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 12&nbsp;times (mice) and 57&nbsp;times (rats) the human exposures at the RHD.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Oral carcinogenicity studies in rats and mice only revealed a low incidence of duodenal tumours at an extremely high-dose in mice. These tumours are unlikely to be of relevance to humans.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Doravirine was not genotoxic in a battery of <em>in vitro</em> or <em>in vivo</em> assays.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Lamivudine was mutagenic in an L5178Y mouse lymphoma assay and clastogenic in a cytogenetic assay using cultured human lymphocytes. Lamivudine was not mutagenic in a microbial mutagenicity assay, in an <em>in vitro</em> cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Tenofovir disoproxil was mutagenic in the <em>in vitro</em> mouse lymphoma assay and negative in an <em>in vitro</em> bacterial mutagenicity test (Ames test). In an <em>in vivo</em> mouse micronucleus assay, tenofovir disoproxil was negative when administered to male mice.</p><p>&nbsp;</p><p><u>Impairment of fertility</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>There were no effects on fertility, mating performance or early embryonic development when doravirine was administered to rats at up to 7&nbsp;times the exposure in humans at the RHD.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Lamivudine did not affect male or female fertility in rats.</p><p>&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters.</p><p>&nbsp;</p><p><u>Repeat dose toxicity</u></p><p>&nbsp;</p><p><em>Doravirine</em></p><p>Administration of doravirine in animal toxicity studies was not associated with toxicity.</p><p>&nbsp;</p><p><em>Lamivudine</em></p><p>Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity. At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reductions in liver weight. The clinically relevant effects noted were a reduction in red blood cell count and neutropenia.<br />&nbsp;</p><p><em>Tenofovir disoproxil</em></p><p>Findings in repeat-dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use included kidney and bone changes and a decrease in serum phosphate concentration. Bone toxicity was diagnosed as osteomalacia (monkeys) and reduced bone mineral density (BMD) (rats and dogs). The bone toxicity in young adult rats and dogs occurred at exposures &ge;&nbsp;5-fold the exposure in paediatric or adult patients; bone toxicity occurred in juvenile infected monkeys at very high exposures following subcutaneous dosing (&ge;&nbsp;40-fold the exposure in patients). Findings in the rat and monkey studies indicated that there was a substance related decrease in intestinal absorption of phosphate with potential secondary reduction in BMD.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Croscarmellose sodium (E468)</p><p>Hypromellose acetate succinate</p><p>Magnesium stearate (E470b)</p><p>Microcrystalline cellulose (E460)</p><p>Silica, colloidal anhydrous (E551)</p><p>Sodium stearyl fumarate</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>&nbsp;</p><p>Carnauba wax (E903)</p><p>Hypromellose (E464)</p><p>Iron oxide yellow (E172)</p><p>Lactose monohydrate</p><p>Titanium dioxide (E171)</p><p>Triacetin (E1518)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p><p>&nbsp;</p><p>Store in the original bottle and keep the bottle tightly closed to protect from moisture. Do not remove the desiccant. This medicinal product does not require any special temperature storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with silica gel desiccants.</p><p>&nbsp;</p><p>The following pack sizes are available:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 bottle with 30&nbsp;film-coated tablets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90&nbsp;film-coated tablets (3&nbsp;bottles of 30&nbsp;film-coated tablets)</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem 
The Netherlands

Manufacturer:
MSD International GmbH, Kilsheelan, Clonmel, Co. Tipperary, Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>